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ABSTRACT (in English) 
 








substrates.  We  found  that  endometrial  cancer–associated  SPOP  mutants  preferentially  degrade  these 
proteins and the resulting reduction of their levels sensitized cancer cells to BET inhibitors in vitro and in vivo 
using xenograft tumor models. Conversely, prostate cancer–specific SPOP mutations resulted  in  impaired 

















aux  enzymes  E3s  ‐  et  la  dégradation  de  la  protéine  ainsi marquée  via  le  complexe  protéolytique  du 












sein  du même  domaine,  induisent  une  réponse  opposée  en  terme  de  traitement  thérapeutique.  Plus 
précisément, notre étude  fournit un  rationnel moléculaire pour  l’utilisation des BET‐i, déjà présent dans 
plusieurs essais  cliniques pour  certains  types de  cancer.  Les mutations du gène SPOP peuvent ainsi être 


























1. Principles of Cancer 








alterations  that  activate  oncogenes  and  inactivate 
tumor  suppressors.  This  process  leads  to  the 
transformation  of  normal  cells  into malignant  and 
unconstrained  proliferative  cells  that  escape  the 
mechanisms of normal homeostasis in the organism.  
In  2000,  Douglas  Hanahan  and  Robert  Weinberg, 
conceptualized  cancer  under  six  hallmarks  that 
contain  the  biological  capabilities  acquired  during 
tumor  growth  and  metastatic  dissemination.  They 
include  sustaining  proliferative  signaling,  evading 
growth  suppressors,  resisting  cell  death,  enabling 











Indeed,  though disruption of  gene expression,  they  can  affect one or  several  targets  involved  in  cancer 
progression, for example by activating or repressing specific genes, deregulating the transcription machinery 
or disturbing the steady‐state levels of specific proteins. 
2. Somatic mutations  
The first insights about the crucial role of the genome in cancer development were described by David von 







germline  mutations  that  are 
inherited  and  transmitted 
from  parents.  They  can  be 
acquired  at  an  early  stage  in 
embryonic cell division, which 
leads  to  their  presence  in 
almost all of the somatic cells 
(Figure  3).  Some  of  the well‐
established  genomic  changes 
are  common  to many  tumor 
types,  whereas  others  are 

































chart area reflects  the proportion of  the  total number of cases or deaths; nonmelanoma skin cancers are  included  in  the “other” 
category. Source: GLOBOCAN 2018[10]. 
Prostate cancer  incidence rate varies greatly across regions and populations (Figure 6) [10]. The strongest 
established  risk  factors  for prostate  cancer are  the age, ethnic group, and  family history  [11]. However, 
differences  in  social,  environmental  and  genetic  have  also  been  established  as possible  reasons  for  the 








other  hand,  Africa  and  Asia  display  lower  incidence  rates  than  those  from  developed  countries.  The 
worldwide  variations  in  PCa  incidence might  be  attributed  to  differences  in  health  care  access  and  to 




























































At  the histological  level, prostatic  intraepithelial neoplasia  (PIN)  is  characterized by  the manifestation of 
atypical cytological features of the epithelial cells in prostatic glands or ducts and is widely accepted as the 
precursor of prostate tumorigenesis [31].  High‐grade PIN (HG‐PIN) has been suggested to be the transition 








4. Evolution and therapeutic options 
 
a) Localized Prostate cancer 
Localized PCa is thus an early stage of malignancy that is restrained to the prostate itself and is considered 





















Figure  10.  Simplified  mechanism  of  the  androgen  receptor 
signaling  in  the  prostate  cells.  Inspired  by  Punit Saraon  et  al, 
Clinical  Chemistry,  2011  [40].  Testosterone  in  the most  secreted 
androgen of  the male  circulation, and  is mainly produced by  the 
Leydig  cells  of  the  testes  through  the  hypothalamus  axis.  Free 
circulating testosterone can enter prostate cells and be converted 





c) Castration Resistant Prostate Cancer (CRPC)  
Although ADT  remains universally accepted as  the  first‐line standard of care of PCa with  initial  response 
reaching  about  80%  of  the  patients, many  patients  develop  disease  relapse  and  progress  to  androgen‐
independent  prostate  cancer,  identified  as  castration  resistant  prostate  cancer  (CRPC)  (Figure  11)  [41]. 
Indeed, in about 20‐40% of the patients, prostate cancer re‐occur and metastasis to the bones, lymph nodes 
and  bladder  [42‐45].  Patients  with  metastatic  CRPC  (mCRPC)  are  often  treated  with  chemotherapy 
(docetaxel), or  later on with abiraterone (inhibition of androgen production), enzalutamide (antagonist of 































































nucleotide  variants  (SNVs),  CNV  and  gene  fusions  revealed  genomic 
alterations in AR, ETS family members, TP53, PTEN, and RB1 as the most 
frequently found (Figure 13) [56]. High fraction of oncogenic mutations 








neuroendocrine  cancers  and  the  aggressive  phenotype  of  this 
association  found  in  several  prostate  cancer  models  [58‐61]. 



























activity)  [68‐70].  Ethnical  disparities  are  also 










3. Diagnosis  
ECa  is generally diagnosed rather soon as the disease often produces symptoms at relatively early stages. 
Unusual  vaginal  bleeding  is  a  common  sign  of  endometrial  cancer  that may  lead  to  biopsy.  Complex 
hyperplasia with atypia is often a precursor of type 1 endometrial cancer. Almost all ECa start in the glandular 
cells of the endometrium and are defined under the endometrioid adenocarcinomas subtype. 

















Table  2.  Dual  classification  of 







overexpression  HER‐2/neu.  They  are  considered  as  higher‐grade  adenocarcinomas  and  under  the  non‐
endometrioid subtype.  
Finally,  integrated genomic analysis of endometrioid and  serous carcinomas by TCGA  in 2013,  led  to  the 



































a) Endometrioid Carcinoma 
As mentioned  above, endometrioid  carcinoma  is  the most  common  type of endometrial  carcinoma  and 
account for approximately 85% of cases. Based on the presence of specific types of cellular differentiation it 
is usually divided into usual and variant types. The usual types are composed of large glands with complex 








b) Serous Carcinoma  
The serous type represents about 3‐10% of ECa and exhibit the most aggressive phenotype with a rather high 
number of deaths. One of its main distinguished feature is a marked nuclear atypia when compared to low‐




an early event  in  the pathogenesis  [76, 80‐82]. Perturbations  in p53 and  its  relevance  in the  initiation of 
serous  carcinoma,  have  been  further  underscored  by  a mouse model  in which  deletion  of  TP53  in  the 











































29%),  PPP2R1A  (13–27%),  and  FOXA2  (5–15%)  [85,  95‐99].  Interestingly  about  67  to  78%  of  uterine 
carcinosarcoma  bear  molecularly  resemblance  to  serous  carcinomas,  and  22–33%  to  endometrioid 
carcinomas. Other putative driver genes are RB1  (4–11%), U2AF1  (4%), ZBTB7B  (11%), ARHGAP35  (11%), 



















adjuvant  treatment of high‐risk  recurrence, advanced disease or  for  treatment of  recurrent disease, or a 
combination with radiotherapy [105, 106]. Hormonal treatment with progesterone has also emerged for the 








SPOP  is  located on  chromosome 17 and was  first  identified  in 1997  [109]. The product protein  is an E3 























as  the  regulation  of  protein  activity  and  their 
localization  and  is  thus  is  associated  with 
practically all cellular process (e.g. transcriptional 
regulation  and  metabolism)  [115‐117]. 
Ubiquitylation  has  a  central  role  in maintaining 
body  homeostasis.  Its  deregulation  is  thus 
associated with several diseases, including cancer 
[121]. Indeed, many E3s are deregulated in cancer 
through  epigenetic  and  genetic  mechanisms 
[122]. 
Figure 17. The enzymatic cascade of ubiquitin transfer. Inspired by Albekairy et al, Int. J. Med. Med. Sci., 2013. 
2. SPOP Structure  














1SPOP MATH BTB  BACK 






The  substrate  recognition site  is present within  the MATH domain, where most of  the cancer‐associated 












3. SPOP in cancer 
Accumulating evidence  suggests multiple  roles  for  the ubiquitin  ligase substrate adaptor protein SPOP  in 
cancer.  Indeed, SPOP is classified as an important cancer gene across 21 different types of cancers (Figure 
20) [128].  However, SPOP exhibits opposing function towards oncogenicity in a context‐dependent manner. 






prognosis.  In  colorectal  cancer  (CRC),  SPOP  has 
also been shown to be downregulated, and linked 













a) Prostate cancer associated SPOP mutations  
In prostate cancer, the heterozygous point mutations cluster in amino acid residues of the substrate‐binding 
cleft (Figure 21) [47]. This specific region within the MATH domain is crucial for substrate binding and implies 
that  the  various mutations might  alter  interaction  and  ubiquitination  of  certain  substrates  in  order  to 




form  with  the  wild  type  protein,  heteromeric  complexes  that  lose  the  ability  to  bind  oncogenic 
substrates[137]. 
Figure 21. Schematic  representation of SPOP  in complex with E3  ligase CUL3.RBX and E2. Wild‐type SPOP  (left) and SPOP PCa‐
associated point mutations (right) are illustrated. 
Several animal models have been generated to understand the physiological role of SPOP in PCa. In zebrafish, 
homozygous deletion of SPOP  led  to  impairment of  the brain, eye and body development  that could be 
rescued through injection of SPOP mRNA. In mice, SPOP ‐/‐, resulted in non‐viable pups with death occurring 
between embryonic day 18.5 and postnatal day 1 [138]. Recently, a transgenic prostate‐specific mouse model 























lead  to  a  nonrandom  distribution,  which  match  the  signature  of  cancer  driver  events  (Figure  22). 
Consequently, SPOP is a significantly mutated gene in endometrial cancer [128]. 
Figure 22. Recurrent SPOP mutations in endometrial and prostate cancer. Left:   Outer surface of the SPOP substrate recognition 
domain with  recurrently mutated  amino  acid  residues  highlighted  in  blue  for  prostate  cancer  and  red  for  endometrial  cancer, 
respectively [112]. Substrate in green in the substrate binding cleft. Right: Histogram of SPOP mutations as detected in three genomic 
studies of endometrial cancer and carcinosarcoma, mutation depicted with an allelic fraction of 0.1 or higher [86, 98, 133]. 
In  contrast  to prostate  cancer, where  SPOP mutant  tumors  retain one wild  type  SPOP allele, 20‐30% of 
endometrial tumors lack SPOP wild type DNA [133].  Besides, an endometrial cell line with a recurrent SPOP 
mutation (EN cancer cell line, SPOP‐R121Q) harbors only mutant SPOP DNA. The loss of the wild type allele 
may have functional  implications  in tumorigenesis.  Indeed, since mutant and wild type SPOP are  likely to 
form  oligomers,  they  may  have  different  specificity  to  certain  substrates  when  compared  to  mutant 
oligomers only. The  recurrent mutations of SPOP across endometrial cancer patients  indicate  that  these 

















4. SPOP substrates 
SPOP has thus been shown to exhibit both tumor suppressor and tumorigenic functions through its specific 
substrates and their role towards cancer progression. To date, more than 30 targeted proteins have been 
found  to  be  specifically  regulated  by  SPOP  (Table  4). Overall,  SPOP  targets  a wide  range  of  biological 






















Endometrial  ERα : Estrogen Receptor  Nuclear hormone receptor  [157] 
Gastric  Gli2  Transcription factor  [158] 
















































































removing  these marks.  It  comprises  histone  deacetylases  (HDAC),  demethylases,  and  phosphatases.  (3) 
Epigenetic readers are a class of proteins scaffolds that are specialized in recognizing the specific covalent 





acetylation  (Ac),  phosphorylation  (Ph)  and  ubiquitination  (Ub). 
Epigenetic  writers  add  chemical  modifications,  erasers  remove  the 






2. Biology of BET family proteins 







proteins  are  part  of  larger  nuclear  complexes  implicated  in  transcriptional  regulations  and  chromatin 








BRDT  is primarily expressed  in germ cells of  the  testis and plays a role  in spermatogenesis  through gene 
regulation during meiosis whereas BRD2, 3 and 4 are ubiquitously expressed [181]. 
BRD4 
BRD4  is  the most studied and characterized member of  the BET  family.  It recruits  the active  form of  the 




important  for  the  activation  of  its  CDK9  kinase  unit 





component  of  the  NuRD  nucleosome  remodeler)  [185, 




Figure  26.  BET  proteins’ mechanism  of  function.  Adapted  from  Ref.  
[206] 
BRD3 
























Several  studies  reported  that  BET  proteins  promote  disease  progression  through  in  part  the  aberrant 












4. BET inhibitors 
In 2010,  the  study  led by  Filippakopoulos et al.  [209] was  the  first  to  characterize  the  ability of  a  small 
molecule (a thienotriazolodiazepine, JQ1), to competitively inhibit the binding of acetylated histones (Figure 
27). By displacing the bromodomains from the chromatin, JQ1 altered the transcriptional activity of target 























In an additional  study, BAY1238097  treatment  in eight patients with advanced  solid  tumors or NHL was 
stopped because of development of grade 3 headache,  vomiting and  low‐back pain  [216].  Finally,  in an 




























Opposing	 effects	 of	 cancer‐type	 specific	 SPOP	mutations	 on	BET	 protein	
degradation	and	sensitivity	to	BET	inhibitors	
 





dominant‐negative  fashion  to  repress ubiquitination and degradation of oncogenic substrate proteins.  In 
endometrial cancer, recurrent SPOP mutations occur in an uncharacterized territory of the MATH domain. 
Since the mutation pattern is different in these tumor types, we hypothesized that in endometrial cancer, 





changes  in the ubiquitin  landscape that was  induced by the seven recurrent endometrial SPOP mutants  , 



























residues  (degron‐MT,  Supplementary  Fig.  5a).  Using  knockdown,  co‐immunoprecipitation,  time  course 






Through  comparison  of  different  endometrial  cancer  cell  lines,  the  EN  cell  line was  found  to  harbor  a 
recurrent SPOP mutation  (SPOP‐R121Q) at  the endogenous  locus and expressed  the  lowest  levels of BET 
proteins  ( Supplementary Fig 6a and Fig. 3a performed by Hana  Janouskova).  I  found a more significant 
increase in BET protein levels upon SPOP depletion or short‐term proteasome inhibition in EN cells than in 
Ishikawa  cells  (Fig.  3b  and  Supplementary  Fig.  6c–e,  performed  by myself).  In  addition, we  found  that 
endogenous  SPOP‐R121Q  bound more  efficiently  to  BET  proteins  in  EN  cells, with  a more  pronounced 


























levels of each BET proteins  in  response  to endometrial‐SPOP mutants  in  Ishikawa cells correlated with a 
decrease of  the half‐maximal  inhibitory concentration  (IC50) upon  JQ1  treatment  (Fig. 4b, performed by 
myself). Additionally, overexpression of the BRD2, BRD3 and BRD4 degron variants in the sensitive cell line 
SPOP‐E50K Ishikawa cells lead to increased resistance to JQ1 (Fig. 4c and Supplementary Fig. 7g, performed 







in 3D culture conditions across 12 different human cell  lines, and correlated  it with  their  respective BET 
protein levels. Lower levels of BRD2, BRD3 and BRD4 (when compared to Ishikawa cells) were associated with 
sensitivity to JQ1 in many cases (Supplementary Fig. 8a–c, performed by myself).  I also found a couple of 
cell  lines  that  did  not  correlate  and  that  could  be  explained  by  other  previously  established molecular 
mechanisms regulating the response to BET inhibitors [214, 222].  Importantly, the EN cells (SPOP‐R121Q) 
were  highly  sensitive  to  JQ1  inhibition  (Supplementary  Fig.  8b,  performed  by myself). We  looked  for 
additional cell lines with recurrent endometrial cancer–associated SPOP mutations at the endogenous locus 
and  identified  a  colorectal  (NCI‐H508)  and  a  urothelial  (VM‐CUB1)  cancer  cell  lines  in  the  Catalogue  of 
Somatic Mutations in Cancer (COSMIC) Cell Lines Project that harbored SPOP mutations ( E47K and E50K , 
respectively). Both cell lines were particularly sensitive to JQ1, exhibited lower BET protein levels in respect 
to  Ishikawa  cells  and  were  responsive  to  proteasome  inhibition  (Fig.  4e  and  Supplementary  Fig.  8d, 
performed by myself). Taken together, the data show that endometrial cancer–associated SPOP mutations 












histone  tails of  transcriptionally active sites. We  thus decided  to  investigate  the  transcriptional profile of 
Ishikawa cells overexpressing SPOP‐WT and two endometrial cancer and prostate cancer–associated SPOP 
mutants  (Supplementary  Table  2,  performed  by  Anna  Rinaldi  and  Luciano  Cascione)  and  found mainly 
opposing  transcriptional  changes with  SPOP‐WT positioned  in between  the  two  types of  SPOP mutants 
(Supplementary  Fig.  10a,  b  performed  by  Anna  Rinaldi  and  Luciano  Cascione).  Interestingly,  the 
multidimensional scaling (MDS) analysis revealed a second feature that discriminated both types of mutants 
from SPOP‐WT, which could be the reflection of shared SPOP substrates dysregulation such as TRIM24 or 
NCOA3.  Moreover,  we  found  a  significant  overlap  between  the  differentially  expressed  genes  in  the 
untreated  conditions  and  upon  JQ1  treatment  (Fig.  5a,  b  and  Supplementary  Fig.  10a–c,  treatment 
performed by Hana Janouskova, transcriptome analysis performed by Anna Rinaldi and Luciano Cascione).  
We  identified 16  genes with  altered  expression  across  all  conditions  (untreated, 500 nM or 2  μM  JQ1), 
including  FOSL1,  a previously  reported  target  gene  for BET proteins  and  implicated  in  sensitivity  to BET 
inhibitors.  Both  FOSL1 mRNA  and  protein  levels were  reduced  in  cells  that  overexpressed  endometrial 
cancer–specific, as compared to prostate cancer–specific, SPOP mutants (Fig. 5c, performed by myself). Our 
in vitro data correlated as well with human tumor tissues as FOSL1 mRNA and protein levels were decreased 
in  individuals with  endometrial  cancer  harboring mutated  SPOP  (Fig.  5d,  e  and  Supplementary  Fig.  7c, 
performed by Marco Losa and Jean‐Philippe Theurillat). 
As BRD2, BRD3 and BRD4 have been  reported at  the FOSL1 promoter, we  investigated  if changes  in BET 
protein  levels  in  response  to  SPOP mutants  and  JQ1  treatment would  affect  FOSL1  transcription  levels, 
(Supplementary Fig. 10d, generated by Luciano Cascione)[221].   We found that JQ1 treatment decreased 
FOSL1  expression  levels  in  each  cell  type, maintaining  the  relative  differences  between  both  subtypes 
(endometrial  versus  prostate  SPOP  mutants,  Fig.  5f,  performed  by  Hana  Janouskova).  Importantly, 
knockdown of each BET proteins decreased FOSL1 mRNA levels in JQ1‐resistant Ishikawa cells (SPOP‐Y87C) 
(Supplementary  Fig.  10e, performed by Hana  Janouskova)  and  FOSL1  knockdown  itself directly  rescued 
partially the phenotype by  lowering the resistance to JQ1 treatment  in this setting (Fig. 5g, performed by 










endometrial  cancer  cells  (SPOP‐R121Q),  Ishikawa  parental  cells  (  SPOP‐WT)  and  from  Ishikawa  cells 


























in  order  to  verify  that  the  transcription  levels  of  these  proteins were  not  affected  and  thus  confirm  a 
dysregulation at the protein level (Figures 2B, C). I found that SPOP‐T25A, ‐ Y83C, ‐G132V, ‐R138C lead to an 
upregulation of BET protein levels, whereas SPOP‐R121Q and SPOP‐D144N lead to a downregulation of BET 
protein  levels.  We  also  received  patient‐derived  cell  lines  (Epstein‐Barr  Virus  Growth‐Transformed 
Lymphoblastoid  Cell  Lines,  EBV)  for which  I  performed  the  same  experiments  described  previously  for 
Ishikawa cells and we could confirm a similar result than the one in the isogenic system. 
To functionally analyze the effects of SPOP on BET degradations, I then decided to focus on two SPOP variants 
(SPOP‐R138C  and  SPOP‐D144N)  showing  opposing  effects  towards  the  BETs.    I  performed  time  course 
experiments by blocking the protein synthesis using cycloheximide and by blocking the protein degradation 
by  proteasome  inhibition  (MG132).  The  effects  of  SPOP  variants  on  BET  levels,  in  human  Ishikawa 









detectable  rescue of protein  levels when blocking  the proteasome with MG132  (Figure S6). As we were 
collaborating in a double‐blind way, we did not know any of the individuals’ phenotype while providing the 
functional results to our collaborators. Strikingly, we could establish a molecular basis for the contrasting 
phenotype.  Indeed,  the  individuals harboring  the  two gain of  function mutations  (SPOP‐T25A and SPOP‐
D144N)  share  craniofacial  dysmorphisms  including microcephaly.  On  the  contrary,  the  five  individuals 
harboring the dominant‐negative mutations towards BET proteins, had macrocephaly and hypertelorism.  
These findings suggest that the opposite functional effects caused by SPOP mutations result in two distinct 


























xenografts  in  immune‐compromised mice  (Fig.  1c, d performed by  Tiziano Bernasocchi). We performed 
similar experiments  taking advantage of  the  LuCaP147 PDX model harboring a  recurrent SPOP mutation 
(SPOP Y83C) and found that overexpression of ΔERG significantly reduced the growth of the cancer cells in 
vitro and  in  vivo  (Fig. 1e, Extended  Fig. 2a,b performed by Tiziano Bernasocchi). The growth advantage 
conferred    by  the  overexpression  of  the  oncogene MYC  in  both  VCaP  and  LuCaP‐147  ,  confirmed  the 
specificity of the synthetic sick relationship between the two driver genes, and excluded the notion that our 
overexpression  system  is  the  underlying  cause  of  the  observed  phenotype  (Extended  Data  Fig.  2c,  d, 








To understand  the underlying molecular alterations of  the  synthetic‐lethal  relationship of  the  two driver 
genes,  we  then  assessed  the  transcriptional  changes  occurring  in  the  VCaP  cells  in  response  to  SPOP 
mutations.   We analyzed the effect of mutant SPOP (SPOP‐Y87C,  ‐F102C,  ‐F133S) on AR‐ and ERG‐related 
transcription  in VCaP  cells, and generated  custom  signatures using ChIP‐seq data and matched RNA  seq 
samples  (Fig  2a,b,c  and  Extended  Fig  3a‐e,  wet‐lab  experiments  performed  by  Tiziano  Bernasocchi, 
corresponding computational analysis by Marco Bolis) . We found that the androgen receptor (AR) signaling 
pathway was significantly upregulated, while specific ERG target genes were repressed. Indeed, SPOP‐MTs 





















that  the  SPOP‐CUL3  ubiquitin  ligase  complex  degrades  ZMYND11  through  a  conserved  binding  motif 























formation capacity  in 3D methylcellulose assay, and  recapitulated  the  transcriptome changes  induced by 
SPOP mutants exhibiting upregulation of AR signaling pathway and repression of ERG target genes (Extended 
data  7e,f,  performed  by myself  and  corresponding  computational  analysis  performed  by Marco  Bolis). 
Importantly, overexpression of SPOP mutants  ( SPOP‐Y87C,  ‐F102C,  ‐W131G,  ‐F133S) and HA‐ZMYND11‐
DMT2 also decreased the invasion ability of PC3 cells overexpressing ΔERG ( Extended Data Fig. 7g,h and Fig. 
4d,e performed by Tiziano Bernasocchi). Taken together, our data point out towards an  important role of 





























Data  Fig.  9h,i  performed  by myself).  Interestingly,  the  transcriptome  profile  show  induction  of  similar 
molecular changes as for the over‐expression of mutant SPOP (Extended Data Fig. 9a, b performed by Tiziano 
Bernasochi,  corresponding  computational  analysis  performed  by Marco  Bolis).  Importantly, we  found  a 
striking correlation between ERG levels and sensitivity to SPOP‐i and testosterone in vivo (Fig. 5a, performed 
by  Tiziano  Bernasocchi,  Fig.  5b  performed  by myself).  Taken  together,  out  data  suggest  a  therapeutic 
opportunity for SPOP  inhibition or high‐dose androgen therapy  for prostate cancer patients which cancer 
cells express high levels of ERG.   
On  the other hand,  through  reanalysis of published  clinical data, we  found  that  the prevalence of SPOP 





analyze  the  response  of  androgen  deprivation  or  the  anti‐androgen  enzalutamide,  we  overexpressed 
different SPOP variants and ΔERG  in the androgen‐dependent human LAPC4 prostate cancer cells (WT for 
both genes). We found that LAPC4‐mutant SPOP (SPOP‐Y87C, SPOP‐W131G)  cells were sensitive to either 




























and  ECa  respectively).  Even  though  they  occur  in  the  same  substrate‐recognition  domain,  each  genetic 
alteration is specific to its tumor type. In other term, none of them show overlap between both cancer types.  
Several  studies  have  shown  that  PCa  SPOP mutations  stabilize  targeted  proteins  that  are  important  to 
prostate tumorigenesis (e.g. TRIM24, DEK). Regarding ECa SPOP mutations, very few studies have focused on 
their  functional aspects.  In  a  study  from 2015,  Zhang et  al.  showed  that estrogen  receptor‐α  (ERα)  is  a 
targeted substrate of SPOP that facilitates tumorigenesis of endometrial cancer cells [13]. However, we had 
difficulties to recapitulate those data  in our  in vitro cell culture models. More recently, a SPOP−/− mouse 








transcriptional  programs.  In  line  with  the  loss‐of‐function  properties  of  PCa  SPOP mutations  reported 




































of AR, ERG and  their downstream genes were  inhibited by  JQ1  in both SPOP‐WT and PCa SPOP mutant‐
expressing  cells,  suggesting  that  intrinsic BET‐i  resistance was  independent of  the  elevated AR  and  ERG 
signaling in SPOP‐mutated prostate cancer cells. Importantly, both AR and ERG are direct binding‐partners of 
BRD4 bromodomain. They also show  that expression of PCa associated SPOP mutant  increases  the basal 
levels  of  phosphorylation  of  AKT‐mTORC1  proteins,  and  inhibit  JQ1‐induced  inhibition  of  their 
phosphorylation.  They found that the levels of RAC1 and cholesterol biosynthesis genes, that are required 
for the AKT‐mTORC1 pathway activation, are upregulated in SPOP‐mutated prostate tumors in patients. In 
addition,  they  provide  evidence  that  targeting  the AKT  pathway  can  be  a  possible  treatment  option  to 












More broadly, our data  suggest  a paradigm whereby mutations within  the  same domain of  a particular 





the De Vries  lab from the Radboud University  in Nijmegen (Netherlands)  identified seven  individuals with 
neurodevelopment  disorders  and  de  novo  missense  variants  in  SPOP.  As  part  of  a  collaboration,  we 








is  required  to understand  the mechanisms  involved  in head growth  in  individuals with pathogenic SPOP 
variants,  which  could  be  determined  by  specific  signaling  pathways  that  govern  cell  proliferation. 
Interestingly, BET proteins have been shown to be  involved  in cell cycle progression [234].  In mice, BRD2, 






in  the  same way  in macrocephaly.  Interestingly,  a  heterozygous missense mutation  in  BRD4  has  been 
described resulting  in macrocephaly and short stature, resembling the  individuals with dominant‐negative 




proximity  to  the  described  SPOP  degron  (AA:  292‐299), which  could  thus  lead  to  an  increased  protein 
stabilization.  
In  summary,  SPOP  variants  have  been  identified  in  individuals with  intellectual  disability  and  in  tumor 
samples. The data suggest that mutations in SPOP can occur at different times of development, specifically 
germline  versus  somatic  tissue,  and  result  in  different  consequences,  i.e.  neurodevelopmental  delay  or 
cancer respectively. Importantly, the individuals with NDD and de novo SPOP variants could be differentiated 
based  on  their  distinct  craniofacial  dysmorphisms  and  congenital  anomalies,  indicating  the  presence  of 






tumorigenesis.  In the  literature, ZMYND11 has also been described as being  implicated  in developmental 
delay  [238, 239].    Indeed, mutations  in ZMYND11 have been  identified  in patients with autism spectrum 
disorders and  intelectual disability, which support the notion that  the gene  is  implicated  in chromosome 
10p15.3 microdeletion syndrome. The deletions in this region are characterized by several specificities such 
as development delay, speech disorders and brain abnormalities. Two genes within this area are frequently 
deleted,  namely  DIP2C    and  ZMYND11  and  are  thought  to  contribute  to  the  disease.  Several  studies 
implicating  different  patients  with  characteristic  dysmorphic  features  now  exhibit  clear  implication  of 
ZMYND11 [240]. Likewise, other already known or unknown SPOP substrates might as well play a role in the 
resulted growth abnormalities. A possible way to address this aspect would be to differentiate the patient 
derive  cell  lines    (Epstein‐Barr  virus  lymphoblastoid  cell  lines,  EBV  LCLs)  into  neuronal  cells  and  assess 
whether  specific  alterations of  these  substrates would  lead  to  any  changes  in  their  phenotype.  Indeed, 
reprogramming EBV LCLs cells have recently emerged as a successful method to gather more relevant in vitro 
models  [27,  28].    Generating  patient  LCL‐derived  iPCSCs  (LiPCSCs  ,  iPCSCs  for  patient‐specific  induced 
pluripotent stem cells) would thus function as an important tool in disease modeling. A study from the Okano 
lab  in  2016  has  actually  refined  the  established  protocol  and  developed  a method  (direct  neurosphere 
conversion method , dNS method) in which LiPSCs could be differentiated into functional neurons in order 
to study effectively Parkinson’s disease [29]. 
It would  also  be  interesting  to  understand why  these  specific  point mutations,  found  in  cancer‐related 
diseases, are also found at the germline level. The emergence of de novo mutations has been described to 





male  lifetime,  allowing  the  the  accumulation  of  random DNA mutations  and  failure  of  the  DNA  repair 
machinery [244].  De novo mutations could also contribute in giving a growth advantage to spermatogonial 
stem cells, which in term would lead to the clonal expansion of mutant cells in the testis [245]. Mutations in 
genes  involved  in  the RAS–MAPK  pathway  have  indeed  been  shown  to  cause  clonal  expansion  through 





screening  of  SPOP mutations  in  human  cancer  but  also  in  other  diseases,  together  with  a  combined 
proteomics approach, could be of interest to unravel the remaining SPOP functions in disease. At the era of 
big data, and with the recent technology improvements, these studies could be done in a rather near future. 
Finally,  it  is  important  to  establish  the  rational of  SPOP‐targeting  therapeutic  capability while  designing 
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Opposing  effects  of cancer-type-specific SPOP mutants 
on BET protein degradation and sensitivity to BET inhibitors 
 
Hana Janouskova1,2,15, Geniver El Tekle1–3,15, Elisa Bellini4, Namrata D Udeshi5, Anna  inaldi1,2, 
Anna Ulbricht6, Tiziano Bernasocchi1–3, Gianluca Civenni1,2, Marco Losa1,2, Tanya  
Svinkina5, Craig M Bielski5,14, Gregory V Kryukov5, Luciano Cascione1,2 , Sara Napoli1,2, 
Radoslav I Enchev6, David G Mutch7 , Michael E Carney8, Andrew Berchuck9, Boris J N 
Winterhoff10, Russell R Broaddus11, Peter Schraml4, Holger Moch4, Francesco Bertoni1,2, Carlo 
V Catapano1–3, Matthias Peter6, Steven A Carr5, Levi A Garraway5,12,13, Peter J Wild4 & 
Jean-Philippe P Theurillat1–3 
 
It is generally assumed that recurrent mutations within a given cancer driver gene elicit similar drug responses. Cancer genome 
studies have identified recurrent but divergent missense mutations affecting the substrate-recognition domain of the ubiquitin 
ligase adaptor SPOP in endometrial and prostate cancers. The therapeutic implications of these mutations remain incompletely 
understood. Here we analyzed changes in the ubiquitin landscape induced by endometrial cancer–associated SPOP mutations 
and identified BRD2, BRD3 and BRD4 proteins (BETs) as SPOP–CUL3 substrates that are preferentially degraded by endometrial 
cancer–associated SPOP mutants. The resulting reduction of BET protein levels sensitized cancer cells to BET 
inhibitors.Conversely, prostate cancer–specific SPOP mutations resulted in impaired degradation of BETs, promoting their 
resistance to pharmacologic inhibition. These results uncover an oncogenomics paradox, whereby mutations mapping to the 
same domain evoke opposing drug susceptibilities. Specifically, we provide a molecular rationale for the use of BET inhibitors to 
i i h d i l b h h b SPOP i
Specific mutations  in cancer‐related genes can  indicate whether  a 




have  revealed  recurrent  point mutations mapping  to  the  substrate‐




substrate‐recognition  domain  that  is  essential  for  substrate 
interaction  and  ubiquitin  transfer7. We and  others have subsequently 




recognition domain (Fig. 1a and Supplementary Fig. 1a)4–6. Given the 
divergent mutation 
patterns  in  these  tumor  types,  we  speculated  that  SPOP mutations 




Cancer-type-specific SPOP mutations have opposing effects on 
BET protein levels 
To  explore  this  hypothesis,  we  characterized  changes  in  the  ubiqui‐ 
tination  landscape  specific  to  endometrial  cancer–associated  SPOP 
mutants by mass spectrometry–based proteomics. To ensure that dis‐ ease‐
relevant proteins were being expressed  in our experimental  set‐  ting, we 
chose  human  Ishikawa  endometrial  cancer  cells,  derived  from  a  well‐
differentiated  endometrioid  cancer,  for  experimentation  because  their 
robustly expressed genes substantially overlapped with those  found in 
SPOP‐mutant  tumor  tissues  (Supplementary Fig. 1b)6,13. 
Subsequently,  we  generated  cells  that  stably  overexpressed  control 
vector, wild‐type SPOP (SPOP‐WT) or one of seven endometrial 
1Institute of Oncology Research, Oncology Institute of Southern Switzerland, Bellinzona, Switzerland. 2Faculty of Biomedical Science, Università della Svizzera Italiana, 
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Zurich, Zurich, Switzerland. 5Broad Institute of Harvard and MIT, Cambridge, Massachusetts, USA. 6Department of Biochemistry, Eidgenössische Technische 
Hochschule, Zurich, Switzerland. 7Division of Gynecologic Oncology, Washington University, St. Louis, Missouri, USA. 8Department of Obstetrics, Gynecology and 
Women’s Health, John A. Burns School of Medicine, University of Hawaii at Manoa, Honolulu, Hawaii, USA. 9Division of Gynecologic Oncology, Duke Cancer Center, 
Durham, North Carolina, USA. 10Division of Gynecologic Oncology, University of Minnesota, Minneapolis, Minnesota, USA. 11Department of Pathology, University of 
Texas MD Anderson Cancer Center, Houston, Texas, USA. 12Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA. 13Center 
for Cancer Genome Discovery, Dana-Farber Cancer Institute, Boston, Massachusetts, USA. 14Present address: Molecular Oncology, Memorial Sloan Kettering Cancer 
Center, New York, New York, USA. 15These authors contributed equally to this work. Correspondence should be addressed to J.P.T. (jeanp_theurillat@ior.iosi.ch). 



























































a b c Protein expression changes
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Figure 1 Endometrial cancer– and prostate cancer–associated SPOP mutants induce opposing effects on BET protein levels. (a) Outer surface of the SPOP 
substrate-recognition domain. Recurrently mutated amino acid residues in prostate cancer are highlighted in blue and those in endometrial   cancer are in 
red7. The substrate-binding cleft is shown in green. (b) Scatterplot showing expression differences for the indicated proteins in Ishikawa endometrial 
cancer cells expressing SPOP mutants (SPOP-MTs) versus wild-type SPOP (SPOP-WT). Dashed red lines, 2 s.d. (c) Representative western blot validation 
for the indicated proteins in Ishikawa cells stably expressing vector control, SPOP-WT or an endometrial cancer–specific SPOP mutant (n = 5). (d) 
Representative western blot for the indicated proteins in Ishikawa endometrial cancer cells expressing prostate cancer–specific SPOP mutants (n = 3). (e) 
Representative western blot for the indicated proteins in 22Rv1 prostate cancer cells stably expressing prostate cancer–associated SPOP mutants (n = 3). 
In b–d, -actin (ACTB) is used as a loading control. (f) Left, representative images of primary human endometrial cancer tissues stained for BRD2, BRD3 
and BRD4 by immunohistochemistry (IHC) (Supplementary Fig. 4c,d); right, corresponding quantification of protein expression levels in primary tumors 
stratified according to SPOP mutation status. Scale bars, 20 m. (g) Analysis of BRD2, BRD3 and BRD4 expression in primary human prostate cancer tissues 
stratified according to SPOP mutation status (Supplementary Fig. 4g). R correlation coefficients and P values were derived from Kendall’s tau-b. In each 
panel, n indicates the number of independent experiments performed. 
cancer–specific mutated SPOP variants (E47K, E50K, E78K, S80R, M117V, 
R121Q and D140N; SPOP‐MTs) (Supplementary Fig. 1c). In each case, we 
measured  glycine‐glycine  remnants  of  ubiquitinated  lysines  (K‐‐GG)  after 
trypsin digestion and stable isotope labeling of amino  acids in cell culture 
(SILAC)‐based mass spectrometry (Supplementary Fig. 1d)14. All K‐‐GG 
values  (n  =  17,239),  defined  as  ratios  of mutant to SPOP‐WT, were 
normalized  to  the  corresponding  protein  ratios  to  account  for 
ubiquitination‐related changes in protein levels (Supplementary Table 1). 
K‐‐GG  peptide  values  for  cells  expressing  individual  SPOP‐MTs  were 
compared to those from cells overexpressing SPOP‐WT within experiments 
(Supplementary Fig. 2a,c,e,g). 
Because  protein  ubiquitination  is  often  linked  to  proteasomal 
degradation, we asked which differentially expressed K‐‐GG peptides 
showed an inverse correlation with protein abundance 









expressing  SPOP‐MTs,  followed  by  an  increase  in  levels  of  the 
corresponding  protein9,15,16.  Similar  dominant‐negative  patterns  of 
substrate dysregulation by prostate cancer–specific SPOP mutants have 
been reported for TRIM24 and NCOA3 (refs. 8,9,17). 
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substrates  that  are  differen‐  tially  ubiquitinated  and  degraded  by 
endometrial cancer– and prostate  cancer–specific mutants irrespective of 
cellular lineage. In support of  these findings, nuclear levels of BET proteins 
correlated  inversely  with  recurrent SPOP mutations  in human primary 
endometrial cancer tis‐ sues analyzed by immunohistochemistry, whereas a 
positive  correla‐  tion was noted  in primary human prostate cancer 
tissues (Fig. 1f,g and Supplementary Fig. 4). 
BET proteins are bona fide SPOP substrates 
We  sought  to  determine  whether  SPOP  directly  interacts  with  BET 
proteins to promote ubiquitination. In agreement with this hypoth‐ esis, 
the primary amino acid sequences of  the BET proteins con‐  tain  a 
conserved consensus sequence that is a SPOP‐binding motif (Fig. 2a)7. 
We focused on BRD3 for experimental follow‐up because it was the most 
differentially  regulated  BET  family  member  (Fig. 1b).  First,  we 
overexpressed HA‐tagged BRD3  (HA‐BRD3)  harboring  three  threonine‐to‐




relative  to  those  of  controls,  in  agree‐  ment  with  the  notion  that 
endogenous SPOP was not able to degrade  the degron variant (Fig. 2b 
and  Supplementary Fig. 5b).  To  deter‐  mine  whether  the  motif 
mediated  direct  binding  of  SPOP  to  BRD3,  we  performed 
immunoprecipitation experiments  in cells express‐  ing either wild‐type 






cullin‐3  (CUL3)–RING‐box  protein  1  (RBX1)  ubiquitin  E3  ligase 
complex20.  Knockdown  of  CUL3  increased  HA‐BRD3  levels  and 
decreased  BRD3  ubiquitination  relative  to  control  in  293T  cells 
(Supplementary Fig. 5c).  Furthermore,  SPOP‐WT,  along with  RBX1 
and CUL3, directly ubiquitinated wild‐type HA‐BRD3 in vivo and in vitro, 
whereas the degron variant of HA‐BRD3 remained unaffected (Fig. 2d and 
Supplementary Fig. 5d).  Additional  CUL3‐dependent  substrate 
adaptors (kelch‐like family member 9 (KLHL9), KLHL13, KLHL21) failed to 
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Figure 2 BET proteins are bona fide substrates of wild-type SPOP.  
(a) Schema of the BET proteins with the positions of bromodomains 1 
and 2 (BD1 and BD2), the extraterminal (ET) domain, the C-terminal 
domain (CTD) and the ubiquitinated lysines (K--GG) detected by mass  
pectrometry indicated; the SPOP degron motif is depicted in red. Effect 
of transient SPOP-WT overexpression on the levels of HA-tagged wild-
type BRD3 (HA-BRD3-WT) and HA-tagged BRD3 with the mutated degron 
(HA-BRD3-degron-MT) assessed by western blot in Ishikawa cells (n = 
3). (c) Interaction between SPOP-WT and BRD3-WT or HA-BRD3- 
degron-MT. HA immunoprecipitation (IP) (top) and whole-cell extract 
(WCE) (bottom) are shown from transiently transfected 293T cells (n = 
3). (d) In vivo ubiquitination of HA-BRD3-WT and HA-BRD3- degron-MT 
by SPOP-WT. 293T cells were transfected to express 8× histidine (8×His)-
tagged ubiquitin (Ub) and the indicated constructs followed by 3 h of 
MG132 treatment. 8×His-Ub pulldown from lysed cells was performed 
using nickel beads (n = 3). (e) HA-BRD3 protein level determined by 
western blot in Ishikawa cells transiently expressing SPOP-WT and HA-
BRD3 with or without 5 h of MG132 treatment (n = 3). (f) Representative 
western blot of the indicated proteins upon knockdown of SPOP with 
shRNA (left) or siRNA (right) in Ishikawa cells (n = 3). The western blots 
shown in b and d–f are representative. Vinculin (VCL) was used as a 
loading control. In b–f, n indicates the number of independent 
experiments performed. 
The most striking changes were found in proteins that exhibited robust 
upregulation  of  K‐‐GG  peptides  coupled  with  downregulation  of  the 
corresponding protein (Fig. 1b,c and Supplementary Figs. 2 and 3a), 
including DEK,  another  characterized  SPOP  substrate8.  Yet,  the  most 
profound changes at the protein level without concurrent changes at the 
mRNA  level were  found  in BRD3, BRD2 and BRD4  (Fig. 1b,c and 
Supplementary Fig. 3b).  These  bromodomain  and  extraterminal 
(BET)‐motif‐containing  proteins,  which  serve  as  prom‐  ising targets  for 
cancer therapy18, may be increasingly ubiquitinated 



































































a b Cancer-type-specific SPOP mutants induce differential 
ubiquitination of BET proteins 
To  test whether  the  functional properties of endometrial cancer– 






(Fig. 3a). We found that EN cancer cells exhibited  lower  levels of BET 
proteins  despite  having  higher  levels  of  the  corresponding mRNAs 
(Fig. 3a and  Supplementary Fig. 6b).  In  line with  the  notion  that 
enhanced  protein  degradation  by SPOP‐R121Q  leads  to  reduced BET 
protein  levels  in EN cells, we  found more  significant  increases  in  BET 
protein  levels  upon  SPOP  depletion  or  short‐term  proteasome 
inhibition in EN cells than in Ishikawa cells (Fig. 3b and Supplementary 
Fig. 6c–e). In addition  to and in accordance with our observations 
above,  endogenous  SPOP‐R121Q  bound more  efficiently  to  BET 
proteins in EN cells,  in which we noted more pronounced degradation 
of  BET proteins  after inhibition of protein synthesis with cycloheximide 






acid  substitutions within SPOP, we analyzed  the activity of  different 
SPOP  species  side  by  side  in  293T  cells.  Endometrial  cancer–
associated SPOP mutants (E50K and R121Q) bound more strongly  to 
HA‐BRD3  than  SPOP‐WT  did  in  vivo  and  in  vitro,  whereas the 
interaction of the prostate cancer–specific SPOP mutants  W131G  and 
F133L was  reduced  (Fig. 3d and Supplementary Fig. 6h).  In  line 
with this observation, ubiquitination of HA‐BRD3 was increased with the 
endometrial cancer–specific SPOP mutants  and  decreased  with  the 
prostate cancer–specific mutants  (Fig. 3e and Supplementary Fig. 
6i). We next  investigated whether  the  increase  in  ubiquitination 






Sensitivity to BET inhibitors is altered by cancer-type-specific 
SPOP mutations 
Some cancer cells depend on  the presence of BET proteins  for  tumor 
growth and  survival18,21. Therefore, we  sought  to determine whether 
enhanced degradation  of BET  proteins  in  the  context of  endometrial 
cancer–specific SPOP mutants might create specific vulnerabilities;  we 
speculated  that endometrial cancer cells with  low BET protein  levels 
might become particularly susceptible to further reduction of BET protein 
levels. Indeed, EN cells were susceptible to individual knockdown of the 





















































































Figure 3 BET proteins are differentially ubiquitinated and degraded by 
endometrial cancer– and prostate cancer–specific SPOP mutants. (a) 
Representative western blot (n = 4) of BET proteins and SPOP in 
Ishikawa and EN human endometrial cell lines. Statistical significance 
was determined by unpaired, two-tailed Student’s t-test (n.s., not 
significant). Error bars, s.e.m. (b) Representative western blot of the 
indicated proteins in Ishikawa and EN cells with or without 3 h   of 
MG132 treatment (n = 3). (c) Representative western blot of the 
indicated proteins after the specified duration of cycloheximide (CHX) 
treatment in Ishikawa and EN cells (n = 3). (d) Interaction of HA-BRD3 
with SPOP-WT, endometrial cancer–associated SPOP mutants (E50K, 
R121Q) and one prostate cancer–associated SPOP mutant (W131G). 
HA immunoprecipitation (top) and WCE (bottom) are shown from 
transiently transfected 293T cells overexpressing HA-BRD3 and the 
indicated SPOP constructs (n = 3). (e) Effects of SPOP-WT and SPOP 
mutants on in vivo ubiquitination of HA-BRD3 (n = 3). (f) In vivo 
ubiquitination of HA-BRD3- WT or HA-BRD3-degron-MT by SPOP-E50K 
(n = 3). Western blots shown in a–f are representative. ACTB were 
used as loading control. In each legend, n indicates the number of 
independent experiments performed. 
and  endogenous  BET  protein  levels  in  the  presence  of  SPOP‐WT 
overexpression  (Fig. 2e and  Supplementary Fig. 5e).  SPOP was  also 




(Fig. 2f and Supplementary Fig. 5g,h).  In aggre‐  gate, these data are 
consistent  with  a  model  in  which  ubiquitination  of  BET  proteins 
promotes their proteasomal degradation. 
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Figure 4 Cancer-type-specific SPOP mutants alter BET inhibitor sensitivity in an opposing manner. (a) Response to JQ1 treatment by Ishikawa cells stably 
overexpressing SPOP mutants specific to endometrial cancer (E47K, E50K, E78K, S80R, M117V, R121Q, D140N; in grey) or prostate cancer (Y87C, F102C, 
W131G, F133L; in blue) in 3D semisolid cell culture (n = 3). Statistical analysis was performed using two-way ANOVA with Dunnett’s  post test, 112 
degrees of freedom (d.f.). (b) Correlation of IC50 (JQ1), shown in Supplementary Figure 7c, with BET protein levels, as quantified by mass spectrometry, 
in Ishikawa cells stably expressing recurrent endometrial cancer–specific SPOP mutants (R and P values were calculated using Spearman rank correlation). 
Each point represents the change in protein expression of individual SPOP mutants relative to that of SPOP-WT. (c) Response to JQ1 treatment (250 nM) 
by Ishikawa cells stably overexpressing SPOP-E50K and different degron-mutant constructs of the BET proteins (n = 3). (d) Effect of shRNA-mediated 
depletion of BRD2, BRD3 and BRD4 individually on JQ1 (200 nM) sensitivity in Ishikawa cells expressing SPOP-Y87C (n = 3). (e) JQ1 sensitivity of: 
Ishikawa cells expressing SPOP-WT, EN human endometrial cancer cells expressing SPOP-R121Q, NCI-H508 human large intestine cancer cells expressing 
SPOP-E47K and mutant VM-CUB1 human urothelial cancer cells expressing SPOP-E50K in 3D semisolid culture (n = 4). A representative immunoblot for 
the indicated proteins and cell lines is shown. ACTB was used as a loading control. P values in e are indicated above the compared bars (two-way ANOVA 
with Dunnett’s post test, 30 d.f.). Data represent mean  s.e.m. Statistical significance was determined by unpaired, two-tailed Student’s t-test unless 
otherwise specified. *P < 0.05, **P < 0.01, ***P < 0.001. In each legend, n indicates the number of independent experiments performed. 
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Figure 5 Downregulation of FOSL1 sensitizes Ishikawa cells to JQ1 treatment. (a) Venn diagram depicting the overlap of significantly differentially 
expressed genes in Ishikawa cells stably expressing SPOP mutants specific to endometrial cancer (E47K, E50K) versus prostate cancer (Y87C, W131G) 
with or without JQ1 treatment. Overlap corresponds to the number of genes with a significant P value of <0.05 (Benjamini–Hochberg test). (b) Heat 
map showing fold change in expression for the 16 genes in the overlap area of a. (c) FOSL1 mRNA (normalized to cyclophilin expression) (top) and 
FOSL1 protein (bottom) levels of Ishikawa cells stably expressing SPOP-WT or either endometrial cancer– or prostate cancer–specific SPOP mutants 
(shown in gray and blue, respectively; n = 4). VCL was used as a loading control. (d) FOSL1 mRNA expression in data sets of individuals with 
endometrial30 and prostate31–33 cancer stratified according to SPOP mutation status. P values were derived from unpaired t-tests with Welch’s 
correction. RPKM, reads per kilobase of transcript per million mapped reads. Red, SPOP mutants with a strong effect on degradation of BETs; gray, 
SPOP mutants with a less pronounced effect on degradation of BETs as compared to SPOP-WT. Midlines correspond to means. (e) Left, representative 
images of human primary endometrial cancer tissues (n = 239) stained for FOSL1; right, corresponding expression analysis on human primary tumors 
stratified by SPOP mutation status. P values were determined by Kendall’s tau-b. Scale bars, 80 m. (f) FOSL1 mRNA (left) and FOSL1 protein (right) 
expression levels after JQ1 (500 nM) treatment in Ishikawa cells stably expressing SPOP-WT or SPOP mutants specific to endometrial cancer (E47K, 
E50K) or prostate cancer (Y87C, W131G) (n = 3). (g) Left, JQ1 dose-response curves for Ishikawa cells expressing SPOP-Y87C upon FOSL1 knockdown 
(n = 3). P values are indicated below the dose-response curves, as calculated by extra sum-of-squares F test. Right, corresponding western blot 
validation of FOSL1 knockdown. In f and g, ACTB was used as a loading control. In each legend, n indicates the number of independent experiments 
performed. In c, f and g, data are represented as mean  s.e.m. Statistical significance was determined by unpaired, two-tailed Student’s t-test unless 
otherwise specified. *P < 0.05, **P < 0.01, ***P < 0.001. 
particularly susceptible  to  further suppression of BET protein  function.  In 
support of this view, a functional overlap among BET proteins has been 
reported22. 
BET  inhibitors  are  under  clinical  investigation  as  anticancer  thera‐ 
peutics,  including  for  solid  tumors18,21,23,24. We  anticipated  that  the 
susceptibility of cancer cells to these inhibitors might be influenced  by 
differences in BET protein levels corresponding to SPOP mutants.  Indeed, 
forced  expression  of  endometrial  cancer–specific  SPOP mutants  (shown to 
lower BET protein levels) sensitized Ishikawa cells to both BET inhibitors, 
JQ1  and  OTX015,  by  promoting  apoptosis  and  reduc‐  ing  cellular 
proliferation (Fig. 4a and Supplementary Fig. 7b–e)25,26. Similar results 
were  found  in  HEC‐151  and  RL95‐2  endometrial  can‐  cer  cells 
(Supplementary Fig. 7f). We aimed to discover whether changes in 
BET protein  levels contribute  to sensitivity  to  JQ1. To  this end, we 
found that reduced levels of individual BET proteins  in response to 
expression  of  SPOP mutants  in  Ishikawa  cells  cor‐  related with  a 
decrease in the half‐maximal inhibitory concentration  (IC50) during  JQ1 
treatment (Fig. 4b). Functionally, overexpression 
of  the  BRD2,  BRD3  and  BRD4  degron  variants  reduced  SPOP‐E50K‐ 
mediated sensitization to JQ1 (Fig. 4c and Supplementary Fig. 7g). We 
then investigated whether increased BET protein levels in the  context 
of  prostate  cancer might,  on  the  contrary,  induce  resistance  to  BET 
inhibitors. Overexpression of prostate cancer–specific SPOP mutants in 
comparison  to  SPOP‐WT  rendered  Ishikawa  and  22Rv1  cells  more 
resistant  to  JQ1  (Fig. 4a and  Supplementary Fig. 7h,i), whereas 




decreased  BET  protein  levels  in  general might  predict  sensitivity  to 
pharmacologic  BET  inhibition  across  cell  line  models  of  human 
endometrial cancer. For this purpose, we assessed JQ1 sensitivity in  3D 
semisolid culture conditions across 12 different human cell lines, for which 
we  determined  BET  protein  levels  in  parallel.  Decreased  expression 
levels of BRD2, BRD3 and BRD4 were associated with sensitivity to JQ1 in 
many cases (Supplementary Fig. 8a–c); however, 
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Figure 6 Endometrial cancer–associated SPOP mutants sensitize cells to JQ1 treatment in vivo. (a) Tumor growth kinetics (left) and individual tumor 
weight (right) with (n = 9) or without (control; n = 7) JQ1 treatment in xenografts established from EN cells. (b) Tumor growth kinetics (left) and individual 
tumor weight (right) with (n = 7) or without (control; n = 7) JQ1 treatment in xenografts established from Ishikawa cells. (c) Representative histology (n 
= 7) (top) and quantification (bottom) of mitotic and apoptotic cells in EN and Ishikawa xenografts treated with vehicle (control) or JQ1. Scale bar, 50 
m. (d) Tumor growth kinetics (left) and individual tumor weight (right) with (n = 7) or without (n = 6) JQ1 treatment in xenografts established from 
Ishikawa cells stably overexpressing SPOP-E50K. (e) Tumor growth kinetics (left) and individual tumor weight (right) with (n = 6) or without (n = 7) JQ1 
treatment in xenografts established from Ishikawa cells stably overexpressing SPOP-S80R. (f) Model showing the differential effects of cancer-specific 
SPOP mutations on both BET protein levels and sensitivity to BET inhibitors (BETi). Representative images of the indicated number     of tumors (n) for 
each xenograft group are shown in a, b, d and e. Data in a, b, d and e shown as mean tumor volume + s.e.m.; midlines represent means. Statistical 
significance was determined by unpaired, two-tailed Student’s t-test. *P < 0.05, **P < 0.01, ***P < 0.001. 
we also found some notable exceptions to this rule, in agreement with  the 
existence of other molecular mechanisms that regulate suscep‐ tibility to 
BET  inhibitors27,28. Nevertheless, EN  cells expressing  the  SPOP‐R121Q 
mutant were sensitive to JQ1 inhibition, in line with our data generated in 
isogenic cell lines (Fig. 4a,e and Supplementary Figs. 7f and 8b). This 
finding led us to search for additional cell lines with recurrent endometrial 
cancer–associated SPOP mutations at the endogenous locus. We identified 








Moreover,  we  tested  whether  established  SPOP  substrates  might 






Transcriptome analysis identifies FOSL1 as a determinant of 
JQ1 response 
BET inhibitors bind to the bromodomains of BET proteins to displace  them 
from  the  acetylated  histone  tails  of  transcriptionally  active  sites. 
Considering this function, we investigated transcriptional changes in 
response  to  overexpression  of  SPOP‐WT  or  two  recurrent  endometrial 
cancer– and prostate cancer–associated SPOP mutants in Ishikawa cells 
(Supplementary Table 2).  Unsupervised  clustering  and  mul‐ 
tidimensional scaling (MDS) analyses of gene expression revealed mainly 
opposing  transcriptional  changes  in  response  to  expression  of  the 
endometrial cancer– and prostate cancer–associated SPOP mutants, 
with  SPOP‐WT  positioned  in  between  the  different  types  of  SPOP 
mutants  (Supplementary Fig. 10a,b).  This  result  aligns well  with  the 
different  BET  protein  levels  observed  across  the  cell  lines 
(Supplementary Fig. 3f).  Interestingly,  the  MDS  analysis  revealed a 
second feature that discriminated both types of mutants from SPOP‐ WT, 
possibly reflecting shared dysregulation of SPOP substrates such as TRIM24 
or NCOA3 (Fig. 1c and Supplementary Fig. 10b)8. 
Next, we interrogated transcriptional changes under JQ1 treat‐ ment 
in  cells  overexpressing  endometrial  cancer–  versus  prostate  cancer–
associated SPOP mutants and found a significant overlap between the 
differentially expressed genes and  those with altered expression in the 
untreated conditions  (Fig. 5a,b and Supplementary Fig. 10a–c). We 
identified  16  genes with  altered  expression  across  all conditions 
(untreated, 500 nM or 2 M JQ1), including FOSL1, a reported target gene 
for BET proteins implicated in sensitivity to BET  inhibitors29.FOSL1 mRNA 
and  FOSLI  protein  levels were  reduced  in  cells  that  overexpressed 
endometrial cancer–specific, as compared  to prostate cancer–specific, 
SPOP mutants,  in accordance with  the observed changes in BET protein 





























































































































































































































   
 



























study (Fig. 5d,e and Supplementary Fig. 7c)30–33. 
Next,  we  investigated  whether  changes  in  BET  protein  levels  in 
response  to  SPOP mutants and  JQ1  treatment might decrease  FOSL1 
transcription, as  triple occupancy of BRD2, BRD3 and BRD4 has been 
reported at  the FOSL1 promoter  (Supplementary Fig. 10d)24.  JQ1 
treatment  reduced FOSL1 expression  levels  in all conditions, whereas  the 
relative expression  levels  remained  the same between  the differ‐  ent 
types of SPOP mutants (Fig. 5f). Knockdown of individual BET proteins 
decreased  FOSL1  mRNA  levels  in  JQ1‐resistant  Ishikawa  cells 
overexpressing the prostate cancer–specific SPOP‐Y87C variant (Fig. 4a and 
Supplementary Fig. 10e). Moreover, FOSL1 depletion  itself  directly 
lowered resistance to JQ1 in this setting, indicating func‐ tional involvement 










preclinical  study  identifies  SPOP mutations  as  a  clinically  detectable 
biomarker of BET inhibitor response. Thus, the detec‐  tion of specific 
SPOP mutations may be used to select patients who may  (endometrial 
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JQ1 treatment blocks tumor growth in xenografts expressing 
endometrial cancer–specific SPOP mutants in vivo 
Finally, we investigated whether our results showing altered sensitivity to JQ1 
in response to SPOP mutants could be validated in an in vivo setting. For 
this  purpose,  we  focused  on  expression  of  endometrial  cancer–




whereas  Ishikawa‐cell‐derived  tumors  were  largely  resistant  to  JQ1 






endometrial  cancers  in  comprehensive  genome sequenc‐  ing studies2–6. 
Surprisingly, the specific genetic alterations show no  overlap between 
these tumor types, even though they are confined to  the same substrate‐





fide  SPOP  substrates.  Small‐molecule  inhibitors  against  this  group  of 
proteins are under clinical investigation in hematological and  solid tumors 
because of the critical  importance of these proteins  in driving  lineage‐
specific  oncogenic  transcriptional  programs18,21,23,24.  We  found  that 
prostate  cancer–associated  SPOP mutations  impair degradation of BET 
proteins, in line with the loss‐of‐function proper‐  ties of these mutations 
reported previously8,9, whereas endometrial  cancer–associated  SPOP 
mutations  enhance  BET  protein  degrada‐  tion  through  a  gain‐of‐
function mechanism (Fig. 6f). The precise structural basis through which 
endometrial  cancer–associated  SPOP  mutations  enhance  binding  and 
ubiquitination of BET proteins and  other substrates (for example, DEK) 
remains to be further elucidated.  The altered BET protein  levels  in the 
SPOP‐mutant  setting  influence  the  transcription of established  target 
genes, such as FOSL1 (ref. 29),  and  thereby alter  the  susceptibility of 
cancer cells to BET inhibitors. 
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SILAC  labeling  and  cell  culture.  For  SILAC  experiments,  human
Ishikawa  endometrial  cancer  cells  were  cultured  in  DMEM/F12
medium  defi‐  cient in l‐arginine and l‐lysine and supplemented with
10%  dialyzed  FBS  (Sigma‐Aldrich),  penicillin,  streptomycin  and  l‐
glutamine  (Invitrogen),  and  l‐arginine  (Arg‐0)  and  l‐lysine  (Lys‐0),  l‐
arginine  [13C6]HCl  (Arg‐6)  and    l‐lysine‐4,4,5,5‐d4    (Lys‐4),    or
[13C6,15N4]HCl   (Arg‐10)   and   l‐lysine  [13C6,15N2]HCl (Lys‐8) (Sigma‐
Aldrich) for 14 d (10 doublings). All media were  supplemented with  l‐




included  a  cell  line  with  overexpression  of  SPOP‐WT  for  cell  line
comparison within and across experiments. The labeling for this cell line was







mM  EDTA;  2  g/ml  aprotinin  (Sigma‐Aldrich);  10 mg/ml  leupeptin  (Roche 
Applied Science); 1 mM phenylmethylsulfonyl fluoride (PMSF); 50 M PR‐619; 
and 1 mM chloroacetamide. The lysate was cleared by centrifugation at 








quenched with  trifluoroacetic  acid  (TFA), and  the peptide  solutions were 









ml  fractions  were  collected  across  the  entirety  of  the  bRP  separation.  For 
proteome  analysis,  5%  of  each  fraction  was  taken  and  combined  in  a 
noncontiguous manner such that every 24th fraction was combined to create 
24 final fractions. For K‐‐GG  analysis,  the  remainder of each  fraction was 
combined  in a noncontiguous man‐  ner such that every eighth fraction was 
combined  to  create  eight  final  fractions.  Pooled  fractions were  dried 
completely using vacuum centrifugation.  For  enrichment  of  K‐‐GG 
peptides, anti‐K‐‐GG antibody from the PTMScan Ubiquitin Remnant 
Motif (K‐‐GG) kit was used (Cell Signaling Technology, cat. no. 5562). Prior 
to  enrichment,  the  antibody was  cross‐linked  to  protein  A  beads  using 
dimethyl  pimelimidate  (DMP)14.  Peptides  were  recon‐  stituted  in 
immunoaffinity  purification  (IAP)  buffer,  and  enrichment was  com‐  pleted 
































Mass  spectrometry  data  analysis.  Data  were  processed  using  the 
MaxQuant  (version 1.2.2.5) software package. The human UniProt database 
including 248  common  laboratory contaminants was used for searching. The 
enzyme  specifi‐  city was set  to trypsin,  the maximum number of missed 
cleavages was set to 2 for proteome data and 4 for K‐‐GG data, the precursor 
mass tolerance was set to 20 ppm for the first search, and the tolerance was set 
to  6  ppm  for  the main  search. Carbamidomethylation of cysteines was 


















the  significantly  deregulated  K‐‐GG  pep‐  tides were  paralleled with 
opposing effects on total protein expression in the case of SPOP‐MT versus 
SPOP‐WT, protein‐normalized SILAC ratios for K‐‐GG were multiplied by 
their corresponding protein‐level ratio and also  by  −1  (Supplementary 
Fig. 2 and Supplementary Table 1). 













































































All  open  reading  frames  (ORFs)  were  cloned  into  pLX_TRC_307–
mOrange using Nhe1 and Mlu1 (Thermo Fisher Scientific). 
Dose‐response  curves  and  cell‐growth  assays.  Cells  were  seeded 
(between  1 × 103  and 1 × 104  cells/well)  in a 96‐well plate. Cells were 
subsequently treated with serial dilutions of JQ1 or OTX‐015 in media to 




























TRIM24  (sc‐271266,  Santa Cruz),  anti‐NCOA3  (2126, Cell  Signaling), 
anti‐DEK  (610948, BD Bioscience), anti‐ERG  (sc‐271048, Santa Cruz), 
anti‐FOSL1 (5281, Cell Signaling), anti‐VCL (4650, Cell Signaling), anti‐‐







































In  vitro  ubiquitination  and  binding  assays. Wild‐type  and  SPOP‐
binding‐  mutant  (degron‐MT)  constructs  of  HA‐tagged  human  BRD3  were 
purified from transiently transfected HEK‐293T cells. Wild‐type and mutant 





















































































FOSL1,  forward  5‐CTGCAGGCGGAGACTGACAA‐3,  reverse  5‐
TCCGGGATTTTGCAGATGGG‐3;  cyclophilin,  (PPIA),  forward  5‐CAGG 
TCCTGGC ATCTTGTCC‐3, reverse 5‐TTGCTGGTCTTGCCATTCCT‐3. 















were  gen‐  erated. RNA‐seq was performed on  cells  either untreated or 
treated with JQ1  (500 M or 2 M) for 4 h (Supplementary Table 2). Total 
RNA was extracted  using the RNeasy kit (Qiagen), and sample quality was 
assessed  using  the  Agilent  Bioanalyzer.  Library  preparation  (Illumina 
unstranded  TruSeq  Library  includ‐  ing  poly(A)  enrichment)  and  RNA 
sequencing  (Illumina NextSeq  high  output,  v2,1 × 75 bp) was performed by 
Microsynth. Quality of sequencing was analyzed  according to Phred score of 
Illumina and FastQC. Mapping to hg38 was done using STAR 2.52b. Genes 
with  counts per million  (c.p.m.) <0.5 mapped  reads  were  considered not 
expressed and were filtered out. Subsequently, counts were normalized based on 
the number of reads acquired per sample, log2 transformed and subjected to the 
voom  function  of  the  limma package  in Bioconductor.  Signatures were 
derived  by  comparing  samples  in  Supplementary  Table  2  and  the 
following filters were used to define differentially expressed genes: c.p.m. > 



















A2EW  from Washington  University6;  TCGA‐N9‐A4Q8  and  TCGA‐DI‐




84  primary  endometrial  cancer  tis‐  sue samples by  targeted DNA 
sequencing (36 endometrioid carcinomas, 26 serous carcinomas, 11 clear 

















































Statistical  analysis. GraphPad Prism  version  7.00  (GraphPad  Software) 
was used for analysis. Data are depicted as means  s.e.m. unless otherwise 
speci‐  fied.  An  unpaired,  two‐tailed  independent  Student’s  t‐test with 
unequal  vari‐  ance  assumption  was  performed  to  analyze  cell  culture 







Data  availability.  CCLE  data  are  available  online  at 
http://www.broadin‐  stitute.org/ccle/home.  The  original  mass 
spectrometry  spectra  have  been  deposited  in  the  public  proteomics 
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Supplementary Figure 1 
 
 
Supplementary Figure 1 Recurrent SPOP mutations in human endometrial cancer and schematic 
representation of proteomic approach. (a) Histogram of SPOP mutations as detected in three genomic studies 
of endometrial cancer and carcinosarcoma (mutation depicted with an allelic fraction of 0.1 or higher)4-6. (b) 
Overlay and correlation of robustly expressed mRNAs (genes with median RPKM > 10) in human endometrial 
cell lines with the median of pooled mRNAs expressed in SPOP-mutant endometrial cancer tissues (n=4995)6. 
(c) Western blot (WB) for indicated proteins of Ishikawa cells used for mass-spectrometry that express stably 
vector control, SPOP-WT, or seven different endometrial cancer SPOP mutants. (d) Schematic illustration 
showing the design of the proteomics experiments. Ishikawa isogenic cell line (c) were isotopically labeled 
and divided into four experiments, each of which contained a SPOP-WT cell line as a comparator within and 








Supplementary Figure 2 Protein-normalized K-ԑ-GG changes of Ishikawa cells over-expressing wild-type 
SPOP compared to endometrial cancer SPOP mutants. (a) (c) (e) (g)  Changes in the indicated peptides after 
overexpression of different representative SPOP mutants (E50K, S80R, M117V, D140N). (b) (d) (f) (h) 
Negative connectivity of K-ԑ-GG peptide and protein expression changes after overexpression of indicated 
SPOP mutants. To visualize K-ԑ-GG sites that undergo inverse changes at the protein level, normalized K-ԑ-
GG data shown in panels a, c, e, g were inverted and multiplied by corresponding total protein expression 





Supplementary Figure 3 
 
Supplementary Figure 3 Up- and down-regulated proteins in human endometrial cancer cell lines stably 
expressing SPOP mutants. (a) Expression changes by individual SPOP mutants in indicated proteins with more 
than 3 standard deviations depicted in a heatmap. (b) mRNA expression levels of indicated genes normalized 
to Cyclophilin and control in Ishikawa cells. All error bars, mean ± SEM (n=3). (c) (d) Representative WB for 




cancer SPOP mutants. (e) Representative WB for indicated proteins in 22Rv1 prostate cancer cells expressing 
endometrial cancer SPOP mutants (n=3). (f) Representative WB for indicated proteins of Ishikawa cells stably 
expressing either SPOP-WT or SPOP mutants (two endometrial and two prostate mutants; n=3). N indicates 
the number of  independent experiments performed. (g) Protein expression changes in  human LHMAR cells 
over-expressing wild-type SPOP compared to prostate cancer SPOP mutants (average of SPOP-Y87N and -




Supplementary Figure 4 
Supplementary Figure 4 BET protein immunohistochemistry (IHC) of primary human endometrial and 
prostate cancers. (a) Representative images IHC and corresponding WB for the indicated proteins of Ishikawa 
control and knockdown cells. (b) Table of SPOP-mutant endometrial tumors analyzed by IHC (E: 
endometrioid, S: serous, CC: clear cell, CS: carcino-sarcoma). (c) (d) Cross-tables and statistics using a 3-
tiered IHC scoring system for BRD2, BRD3 and BRD4 of all human endometrial cancer samples, and stratified 
into histological subtypes (R- and p-values Kendall’s tau-b). (e) Representative images of primary prostate 
cancer tissues stained for BRD2, BRD3 and BRD4 stratified accordingly SPOP mutation status (p-value 
Kendall beta-tau). (f) Table of SPOP-mutant prostate tumors analyzed by IHC. (g) Cross-tables and statistics 
using a 3-tiered IHC scoring system for BRD2, BRD3 and BRD4 of all human prostate cancer samples (R- 




Supplementary Figure 5 
 
Supplementary Figure 5 Identification of SPOP degron recognition site within BET proteins. (a) Schema of 
the HA-BRD3-Degron-mutant (-MT) with indication of amino acid substitutions (T249A/T250A/T251A). (b) 
WB quantification of BRD3 protein levels shown in Fig. 2b (n=3). (c) In vivo ubiquitylation of HA-BRD3 in 
293T cells transiently transfected with the indicated knockdown-constructs against CUL3 followed by MG132 
treatment. 8xHis-Ub pull down using nickel beads on lysed cells (n=3). (d) In vitro ubiquitylation of HA-
BRD3. HA-BRD3-WT and Degron-MT was purified by anti-HA immunoprecipitation (IP) from 293T cells 
and incubated with the indicated proteins and subsequently probed for HA by WB (n=3). (e) Representative 
WB of transient over-expression of SPOP-WT in Ishikawa cells with or without MG132 treatment (n=3).  (f) 
IP of individual BET proteins from 293T cells and subsequently probed for the indicated proteins (n=3).  (g) 
mRNA expression changes induced by siRNA-mediated knockdown of SPOP normalized to Cyclophilin in 
Ishikawa cells (n=3).  (h) Representative WB of BET protein levels after cycloheximide (CHX) treatment in 
control and shRNA SPOP Ishikawa cells (n=3). Representative WBs are shown. N indicates the number of  
independent experiments performed. All error bars, mean ± SEM. Statistical significance was determined by 










Supplementary Figure 6 Proteasomal degradation of BET proteins is enhanced in endometrial SPOP-R121Q 
mutant cancer cells. (a) IGV-screen shot of the inverse strand of the genomic SPOP locus of EN endometrial 
cells showing a C to T conversion corresponding to a R121Q substitution. (b)  BRD2/3/4 mRNA levels in 
Ishikawa and EN (n=5). (c), (d) WB and quantification for indicated proteins upon knockdown of SPOP with 
shRNA in Ishikawa and EN cells (n=3). (e) WB quantification of indicated proteins in Ishikawa and EN cells 
with or without MG132 treatment shown in Fig. 3b (n=3).  (f) WB analysis of indicated proteins after 
cycloheximide (CHX) treatment in Ishikawa and EN cells shown in Fig. 3c (n=3).  (g) IP showing the 
interaction between SPOP-WT or SPOP-R121Q mutant with BRD2/3/4 in Ishikawa and EN cells (n=3). (h) 
In vitro binding of HA-BRD3-WT purified by anti-HA IP from 293T cells to indicated recombinant SPOP 
species (n=3). (i) In vitro ubiquitylation of HA-BRD3 (cropped immunoblot). HA-BRD3-WT was purified by 
anti-HA immunoprecipitation from 293T cells and incubated with the indicated proteins and subsequently 
probed for HA by WB. (j) Effect of transiently transfected SPOP-WT and SPOP-MTs on HA-BRD3-Degron-
MT in 293T cells analyzed by WB (n=3). Representative WBs are shown. N indicates the number of  
independent experiments performed. All error bars, mean ± SEM. Statistical significance was determined by 








Supplementary Figure 7 Cancer associated SPOP mutations determine the response to BET inhibitors by 
altering BET protein levels. (a) Effect of BRD2, BRD3 and BRD4 shRNA-mediated depletion on cellular 
growth in EN, Ishikawa, and Ishikawa cells stably over-expressing SPOP-R121Q. Corresponding knockdown 
validation by WB for indicated proteins shown (n=3). (b) Dose-response curves to JQ1 in Ishikawa cells stably 
over-expressing SPOP-WT and four endometrial cancer SPOP-MTs (n=3, p-value is indicated below the dose-
response curves by extra-sum of squares F test). (c) Table of the half maximal inhibitory concentration (IC50) 
to JQ1 of Ishikawa cells stably expressing SPOP-WT and recurrent endometrial cancer mutants. (d) Dose 
response curve to OTX-015 in Ishikawa cells stably expressing SPOP-WT, and four recurrent endometrial 
SPOP-MTs (n=3, p-value is indicated below the dose-response curves by extra-sum of squares F test). (e) 
Quantification of apoptotic and mitotic figures in response to JQ1 in indicated stable Ishikawa cell lines (n=3; 
*P < 0.05, **P < 0.01, unpaired, two-tailed Student’s t-test). (f) Response to JQ1 in HEC-151 and RL-952 
endometrial cancer cells stably expressing SPOP-WT and two endometrial cancer SPOP mutants in 3D culture 
(n=3; ***P < 0.001, unpaired, two-tailed Student’s t-test). (g) Corresponding HA-BRD2/BRD3/BRD4 
Degron-MTs overexpression validation by WB of experiment shown in Fig.4c. (h) Dose-response curves of 
Ishikawa cells expressing SPOP-WT and three prostate cancer SPOP mutants (n=3, p-value is indicated below 
the dose-response curves by extra-sum of squares F test). (i) Response to JQ1 of 22Rv1 prostate cancer cells 
stably expressing SPOP-WT and three prostate cancer SPOP mutants in 3D culture (n=6; ***P < 0.001, 
unpaired, two-tailed Student’s t-test). (j) Corresponding knockdown validation by WB for BRD2/3/4 proteins 
of experiment shown in Fig.4d. (k) Cropped WB of combinatory BETs knockdown in Ishikawa-SPOP-Y87C 
cells showing restoration of JQ1 sensitivity to control level (n=3, p-value is indicated below the dose-response 
curves by extra-sum of squares F test). (l) Effect of single shRNA-mediated depletion of BRD2, BRD3 and 
BRD4 on JQ1 (200nM) sensitivity in 22RV1-SPOP-Y87C cells. Corresponding BETs knockdown validation 
by WB (n=3; ***P < 0.001, unpaired, two-tailed Student’s t-test). Representative WBs are shown. N indicates 





Supplementary Figure 8 
Supplementary Figure 8 Correlation of BET protein levels and JQ1 sensitivity in twelve endometrial cancer 
cell lines. (a) WB of BET protein levels across endometrial cancer cell lines with endogenous wild type SPOP 
(Ishikawa, MFE-296, RL-951, HEC-15, AN3CA, HEC-1B, SNG-II, HEC-1A, KLE, HEC-116, EFE-184) and 
SPOP-R121Q-mutant EN cancer cells. (b) Response to JQ1 in the same panel of endometrial cancer cell lines 
in 3D semi-solid culture conditions (n=3). (c) Correlation of JQ1 (150nM) response (b) with BET protein 
levels quantified by WB and normalized to β-Actin (a) in the same panel of endometrial cancer cell lines (n=3; 
r- and p-value Spearman rank correlation). (d) BRD2/3/4 protein levels by WB in Ishikawa, NCI-H508 and 
VM-CUB1 cells with or without MG132 treatment. Representative WBs are shown. N indicates the number 





Supplementary Figure 9 
Supplementary Figure 9 Reported SPOP substrates do not affect BET protein levels and JQ1 sensitivity. (a) 
Effect of DEK overexpression and shRNA-mediated DEK knockdown on BET protein levels and JQ1 
sensitivity in Ishikawa cells. (b) Effect of TRIM24 overexpression and shRNA-mediated TRIM24 knockdown 
on BET protein levels and JQ1 sensitivity in Ishikawa cells. (c) Effect of NCOA3 overexpression and shRNA-
mediated NCOA3 knockdown on BET protein levels and JQ1 sensitivity in Ishikawa cells. (d) Effect of ERG 
overexpression on BET protein levels and JQ1 sensitivity in Ishikawa cells. Representative WBs are shown. 




Supplementary Figure 10 
 
Supplementary Figure 10 Transcriptome analysis of Ishikawa cells overexpressing SPOP mutants. RNA-
sequencing analysis of Ishikawa cells stably overexpressing either SPOP-WT or cancer SPOP mutants (two 
endometrial (ECa) E47K and E50K, two prostate (PCa) Y87C and W131G) shown as (a) hierarchical 
clustering or (b) Multiple dimensional scaling (MDS) plot. Genes with counts per million above 45 in at least 
2 samples were considered (n= 6384 genes depicted in a-b). (c) Heat maps of differentially expressed genes in 
Ishikawa cells overexpressing endometrial (E47K) and prostate (Y87C) SPOP mutants in presence of JQ1 
(500nM or 2μM). 134 genes were identified to be differentially expressed upon 500nM and 1012 genes upon 
2μM JQ1 treatment. (d) Chip-seq profile of BRD2, BRD3, BRD4 on the depicted downregulated genes (n°= 
12) shown in Fig.5a and b.23 (e) Changes in FOSL1 mRNA expression upon single shRNA-mediated 
knockdown of BRD2, BRD3 and BRD4 in Ishikawa-SPOP-Y87C cells. All error bars mean ± SEM.  P values 






















  REPORT 
De Novo Variants in SPOP Cause Two 
Clinically Distinct Neurodevelopmental Disorders 
Maria  J.  Nabais  Sá,1    Geniver  El  Tekle,2,3,4    Arjan  P.M.   de  Brouwer,1     Sarah  L.  Sawyer,5 Daniela   del  
Gaudio,6    Michael  J.  Parker,7    Farah  Kanani,7   Marie‐José  H.  van  den  Boogaard,8 ,Koen van Gassen,8 
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(p.Asp144Asn),  identified  in the first two  individuals, resulted  in a gain of function, and conversely, the c.73A>G 
(p.Thr25Ala), c.248A>G (p.Tyr83Cys),  c.395G>T (p.Gly132Val), and c.412C>T  (p.Arg138Cys) variants resulted  in a 
dominant‐negative effect. Our findings suggest that these opposite functional effects caused by the variants in SPOP 
result  in  two  distinct  and  clinically  recognizable  syndromic  forms  of  intellec‐  tual  disability  with  contrasting 
craniofacial dysmorphisms. 
Pathogenic  variants  in  a  considerable  number  of  highly
mutable genes lead to cancer when they occur in somatic cells,
and  they can  lead  to neurodevelopmental disorders  (NDD)  if
occur in the germline or early in the embryonic development.1
They  frequently  disrupt  normal  cell  prolif‐  eration  and/or
differentiation  while  evading  cellular  death.  Moreover, 
mutational hotspots  in both  somatic  cell  lines and  germlines 
point  toward  analogous  functional  effects  of  pathogenic
variants. Examples include gain‐of‐function variants in genes of
the RAS‐MAP kinase pathway, such as PTPN11,2,3 and loss‐of‐
function variants  in several genes of  pathways  that  regulate 
chromatin  remodeling,  such  as  ASXL1.4–6  Nevertheless,
recognizing  the  clinical  relevance  and  investigating  the
functional  impact  of  de  novo  missense mutations  in  genes
associated with NDD remains challenging. By using in silico and
in  vitro  analyses, we examined the effect of de novo clustered




SPOP  homodimers  function  as  a  substrate  adaptor  of  a  larger
cullin3‐RING‐based  ubiquitin  ligase  complex  that mediates  the
ubiquitination of target proteins; this ubiqui‐ tination usually leads
to  proteasomal  degradation  of  the proteins.7  SPOP  contains  an
evolutionarily  conserved  me‐  prin  and  tumor  necrosis  factor
(TNF)‐receptor  associated  factor  (TRAF)  homology  (MATH)
domain; a bric‐a‐brac, tramtrack, and broad complex (BTB) domain
(also  known    as  a  POZ  domain);  a  three‐box  domain;  and  a  C‐
terminal  nuclear  localization  sequence.8,9  The  MATH  domain
medi‐  ates  interaction with  protein‐ubiquitin  ligase  substrates,
such as BRD2, BRD3, and BRD4 proteins, which are collec‐ tively
referred to as  BETs.10 
Somatic  missense  SPOP  variants  restricted  to  the  MATH 
domain  are  frequently  identified  in  prostate  cancer11,12  and 
endometrial cancer.10,13 Indeed, with up to 6–15% of localized 
prostate  tumors  harboring  acquired  heterozygous  missense 
SPOP  variants,  SPOP  is  the  most  commonly  point‐mutated 
gene in prostate cancer.12 These missense SPOP variants act in 
a  dominant‐negative  fashion  to  repress  ubiquitination  and 
degradation of oncogenic 





Utrecht, 3584 CX Utrecht,  the Netherlands;  9Department of Medical Ge‐ netics, University of British Columbia, Vancouver, BC V6H 3N1, Canada;  10University of 
Oklahoma Health Sciences Center, Oklahoma City, OK  73104, USA; 11Special Care Clinic, Children’s Hospital Colorado, Aurora, CO 80011, USA; 12University of Colorado 
School of Medicine, Aurora,         CO 80045, USA; 13GeneDx, Gaithersburg, MD 20877, USA; 14Center for Molecular and Biomolecular Informatics, Radboud Institute 
for Molecular         Life Sciences, Radboud University Medical Center, 6525 GA Nijmegen, the Netherlands; 15Department of Human Genetics, Radboud  Institute for 
Molecular Life Sciences, Radboud University Medical Center, 6525 GA Nijmegen, the Netherlands 
16These authors contributed equally to this work 
*Correspondence:  jean‐philippe.theurillat@ior.usi.ch  (J.‐P.P.T.),  bert.devries@radboudumc.nl  (B.B.A.d.V.) 
https://doi.org/10.1016/j.ajhg.2020.02.001. 





















Two  unrelated  individuals  with  the  same  de  novo  SPOP 
variant  were  identified  via  trio‐based  clinical  exome 
sequencing.  One  was  in  a  cohort  of  4,749  individuals  with 
unexplained  intellectual  disability  (ID)  ascertained  by  the 
Department of Human Genetics of Radboud University Medical 
Center  (Nijmegen,  the  Netherlands),  and  the  other  was 
ascertained at the Department of Genetics, University Medical 
Center Utrecht  (Utrecht,  the Netherlands). A  third  individual 
was  identified  in  a  cohort  of  1,133  children  with  severe, 
undiagnosed  devel‐  opmental  disorders  through  the  DDD 
research  variant  list  on  DECIPHER.18  Additionally,  four 
individuals  with  SPOP  variants  detected  by  clinical  exome 
sequencing were identified via GeneMatcher.19 One girl with ID 
was referred to the Molecular Diagnostic Laboratory at the Uni‐ 
versity  of  Chicago  for  clinical  exome  sequencing  (Chicago, 
Illinois, USA). The other individuals were selected from a cohort 
of 14,183 individuals who had neurodevelopmen‐ 




institutional  review  board  Commissie  Mensgebonden
Onderzoek  Regio  Arnhem‐Nijmegen  un‐  der  CMO  approval 
number NL36191.091.11. 
Six  unique  de  novo missense  variants  in  SPOP  (GenBank: 
NM_001007226.1) were identified in peripheral blood of these 
seven  individuals  with  intellectual  disability:  c.73A>G, 
p.Thr25Ala;  c.248A>G,  p.Tyr83Cys;  c.362G>A,  p.Arg121Gln; 
















Table 1. De Novo Likely Pathogenic Variants in SPOP 
Amino Acid 
Change b,c 
CADD Predicted Effect on 
the Protein 28–30,d cDNA Change a,c Location Mutation Type Domain Affected Individuals 
Exon 5  c.73A>G  p.Thr25Ala  missense  26.0  not in a domain  disease causing  individual 4 
Exon 7  c.248A>G  p.Tyr83Cys  missense  25.6  MATH  disease causing  individual 7 
Exon 8  c.362G>A  p.Arg121Gln  missense  32  MATH  disease causing  individual 1 
Exon 8  c.395G>T  p.Gly132Val  missense  32  MATH  disease causing  individual 3 
Exon 8  c.412C>T  p.Arg138Cys  missense  28.3  MATH  disease causing  individuals 5 and 6 
Exon 8  c.430G>A  p.Asp144Asn  missense  28.9  MATH  disease causing  individual 2 
aGenBank: NM_001007226.1.bGenBank: NP_001007227.1. cNone of these SPOP variants were identified in the gnomAD. 
dWith the exception of p.Arg121Gln, which was predicted to be benign by PolyPhen-2, all variants were predicted to be disease causing by SIFT (v. 6.2.0), Mu- 




specific  facial  dysmorphisms,  in  partic‐  ular  (relative) 
macrocephaly, a high and broad forehead, and hypertelorism.
Additional  overlapping  phenotypic  abnormalities confined to
the second group of five individ‐ uals were failure to thrive and 
short  stature  (2/5),  cardio‐  vascular  abnormalities  (4/4), 
endocrine  abnormalities  (3/4),  epilepsy  (2/4),  and  sleep
disturbance  (4/5). 
On the basis of the previously reported opposite func‐ tional 
effect of  somatic  SPOP  variants  in prostate and endometrial 
cancer  (Table  S2),10we  hypothesized  that  the  divergent 
phenotype of the two groups of individuals corre‐  sponds  to 
differential functional effects. We envisaged that  the  de  novo 
variants, including p.Arg121Gln, that were identified in the first 





in which we  introduced  all  de  novo  SPOP  variants.  Variants 
p.Arg121Gln and p.Asp144Asn resulted in reduced amounts of 
the BET proteins BRD2, BRD3, and BRD4, sug‐ gesting that these 




amounts and are hence  SPOP  variants  such as  those  seen  in 
prostate cancer and are acting in a dominant‐negative manner. 
Importantly,  and  in  conjunction  with  the  notion  of  altered 
protein  stability, we  did  not  observe  relevant  transcriptional 
changes in BET proteins in response to these mutants (Figure 
S4B). We confirmed the nature of the variants by measuring the 
kinetics  of  protein  degradation  by  using  two variants  that 
represent  either  gain‐of‐function  or  domi‐  nant‐negative 
effects.  Indeed,  after  inhibition  of  protein  synthesis  with 
cycloheximide, BET amounts remained 
conserved down to C. elegans (Figure S1). None of the variants 
were  reported  in  the  Genome  Aggregation  Database 
(gnomAD),20 and the CADD (combined annotation‐ dependent 
depletion)  score21  was  higher  than  25  for  all  variants.  In 
ExAC,20 SPOP contains fewer missense variants than expected 
(Z score ¼ 4.74), and no loss of function variant is described (pLi 




the  ratio    of  observed  missense  and  synonymous  (dN  =dS) 
variants that are  included  in gnomAD r2.020 and are found  in 
the protein‐coding region of SPOP. All de novo SPOP variants 
are located in regions that are extremely intolerant to missense 
variants (Figure S2). We  investigated the 3D  loca‐  tion of  the 
variants by using the experimentally solved 3D‐ conformation of 
the dimeric  SPOP  structure  (PDB  file  3hqi;  Figure 2A).25 The 
structure  was  analyzed  with  the  YASARA  and  WHAT  IF 
Twinset.26,27  This  analysis  suggested  that  four  of  the  six 
substitutions,  p.Tyr83Cys,  p.Arg121Gln,  p.Gly132Val,  and 
p.Arg138Cys, would directly affect the binding of substrates to 
SPOP. For the p.Asp144Asn and p.Thr25Ala variants, prediction 




Reverse  deep  phenotyping  of  the  seven  individuals  re‐ 









include  congenital  microcephaly,  hearing  loss,  and  a 
recognizable 






































stable  upon  expression  of  SPOP‐p.Arg138Cys.  In  contrast,
protein half‐life was more dramatically reduced upon expression
of  SPOP‐p.Asp144Asn  as  compared  to  that  of  wild‐type  SPOP
(Figure S6). Consistent with  the notion    that BETs are degraded
through  the  proteasome,  treatment with MG132  restored  BET
amounts  in  both  contexts.  Pro‐  band‐derived  EBV‐immortalized
peripheral blood mononuclear cell (PBMC)  lines from  individuals
1,  2,  3,  4,  6,  and  7 were  additionally obtained  and  cultured  as
previously described.31 Notably, measurements of BET amounts in







or  increased  (individuals  3–7)  BET amounts.  Furthermore, 
variants resulted in growth abnormalities, including a head size 
spectrum  ranging  from microcephaly  to  macrocephaly  and 
distinct recognizable facial dysmorphisms. Whereas individuals 
with  gain‐of‐function  variants  presented with microcephaly, 
individuals  with  variants  leading  to BET’s  functional  loss had 





variability.  So  far, no  true  congenital macrocephaly has been
observed, although birth HC measurements of in‐ dividuals 5, 6,
and  7 were unknown.  Specifically,  individuals  3  and  4, who
were  born  with  below  average  HC,  showed  postnatal
ventriculomegaly,  which  also  contrib‐  uted  to  absolute  or
relative macrocephaly,  respectively. Additional investigation is
needed  if  we  are  to  understand  the  intricate  mechanisms
involved  in head growth  in  individuals with pathogenic SPOP





cells,  whereas  their  amounts  remained  unaltered  in  prolif‐
erating neural progenitor cells.34 In addition, in Brd2‐deficient
neuroepithelial  cells,  cell‐cycle  progression  was  accelerated,
whereas neuronal differentiation as well as cell‐cycle exit were
impaired.35  These  results  correlate well  with  the  congenital
microcephaly  found  in  two  individuals  with  a  STOP  gain of
function resulting in fewer BET proteins and, hence, supposedly
less  neuronal  differentiation.  Conversely, more BET proteins
would  stimulate  the  latter  process,  which  might  result  in
macrocephaly.  Lastly,  a  c.910C>T  (p.His304Tyr;  GenBank:
NM_058243.2) hetero‐  zygous missense  variant  in BRD4 has
been described as resulting in macrocephaly and short stature,
resembling 






features  in  individuals  with  dominant‐negative  variants  in




variation  in  the  same gene are  increasingly  recognized  (e.g. 
CDKN1C37 and RAC138). Different explanations that have been 
proposed  for  the  resultant  excess  or  inhibition  of  cell 
proliferation and differentiation include disruption of a single 
neurodevelopmental  step  that  is  sensitive  to  gene  dosage39 
and  the  possibility  of  a  gene’s  influencing  several  biologic 
pathways  resulting  in  different  consequences depending on 
temporal  and cellular contexts within a genetic background.1 In 
particular, the (re)occurrence of specific genetic variants in the 
substrate‐binding  MATH  domain  of  SPOP,  which  results  in 
opposite functional effects,  emphasizes  the  key  role  of  this 
domain in cell biology. 




consequences,  i.e.,  neurodevelopmental  delay  or  cancer, 
respectively. Individuals with NDD and de  novo SPOP variants 
could  be  differentiated  on  the  basis  of  distinct craniofacial 
dysmorphisms and congenital anomalies, indicating the presence 
of  diverse  clinically  recognizable  intellectual‐disability 
syndromes.  The  opposing  effects  of  variants  impairing  SPOP 
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Driver genes with a mutually exclusive mutation pattern across tumor genomes are thought to have 
overlapping roles in tumorigenesis. In contrast, we show here that mutually-exclusive prostate cancer 
driver alterations involving the ERG transcription factor and the ubiquitin ligase adaptor SPOP are 
synthetic sick. At the molecular level, the incompatible cancer pathways are driven by opposing 
functions in SPOP. ERG up-regulates wild type SPOP to dampen androgen receptor (AR) signaling and 
sustain ERG activity through degradation of the bromodomain histone reader ZMYND11. Conversely, 
SPOP-mutant tumors stabilize ZMYND11 to repress ERG-function and enable oncogenic androgen 
receptor signaling. This dichotomy regulates the response to therapeutic interventions in the AR 
pathway. While mutant SPOP renders tumor cells susceptible to androgen deprivation therapies, ERG 
promotes sensitivity to high-dose androgen therapy and pharmacological inhibition of wild type SPOP. 
More generally, these results define a distinct class of antagonistic cancer drivers and a blueprint toward 
their therapeutic exploitation. 
Normal cells transform into cancer cells by the acquisition of genetic aberrations in so-called driver genes. 
In some instances, the functional redundancy of mutations in different genes result in a mutually-exclusive 
mutation pattern across tumor genomes because one alteration is sufficient to activate the specific oncogenic 
pathway. Based on this assumption, bioinformatic tools have been generated to search for functional 
redundancy of mutated genes in larger cancer genome data sets [247, 248]. 
In prostate cancer, recurrent gene fusions involving the ERG transcription factor and point mutations in 
the ubiquitin ligase adaptor SPOP are two truncal mutations that are mutually exclusively distributed across 
tumor genomes (Fig. 1a and Extended Data Fig. 1a)[47-51]. The underlying cause for this exquisite pattern 
remains controversial. While earlier reports suggested a functional redundancy between mutant SPOP and 
ERG based on the finding that mutant SPOP stabilizes the ERG oncoprotein[147, 249], more recent studies 
challenge this view by showing descriptive evidence for divergence in tumorigenesis[51, 250]. 
RESULTS 
Activation of the ERG oncogene and missense mutation in SPOP are synthetic sick 




SPOP mutations and ERG activation on the cellular growth of mouse prostate epithelial organoids. In 
agreement with recent reports, lentiviral-transduced point mutants of SPOP (SPOP-Y87C, SPOP-W131G) or 
a truncated version of ERG, which typically results from gene fusion with androgen-regulated genes in prostate 
cancer (ERG, amino acids 33-486), promoted cell growth (Fig. 1b, Extended Data Fig. 1b)[57, 139, 251, 
252]. While SPOP mutant organoids displayed a round shape, the over-expression of ERG gave rise to 
characteristic finger-like protrusions. Surprisingly, the joint expression of both drivers considerably 
diminished cell growth and reduced finger-like protrusions, implying a synthetic sick relationship between the 
two genetic alterations. Cytological follow up analysis revealed reduced proliferation (evidenced by reduced 
Ki-67 and increased p16 positivity) rather than cell death as underlying cause (Extended Data Fig. 1c).  
We wondered if the observed synthetic sick relationship also applied to established cancer cells from 
advanced, castration-resistant metastatic disease. Forced expression of mutant SPOP (SPOP-Y87C, SPOP-
W131G) promoted 3D growth of ERG fusion-negative LAPC-4 human prostate cancer cells. The oncogenic 
effect was paralleled by an increase in the expression of the oncogenic transcription factors MYC and HOXB13 
and a decrease in the cell cycle inhibitor p21 as seen also in an organoid line derived from SpopF133V-mutant 
transgenic mice (Extended Data Fig. 1d, e)[139]. In contrast, we observed the opposite phenotypic and 
molecular changes in VCaP human prostate cancer cells harboring the recurrent TMPRSS2-ERG fusion (Fig. 
1c, d & Extended Data Fig. 1f-h). In this setting, mutant SPOP (SPOP-Y87C, -F102C, -W131G, -F133S) 
dramatically decreased the proliferation of cancer cells in culture and the growth of xenograft tumor models 
in vivo. Conversely, forced expression of ΔERG significantly reduced the growth of SPOP-Y83C mutant 
LuCaP-147 patient-derived xenograft (PDX) cancer cells in vivo and in culture (Fig. 1e, Extended Data Fig. 
2a, b)[253], adding orthogonal support for a synthetic sick relationship between mutant SPOP and ΔERG in 
advanced prostate cancer. In addition, over-expression of MYC promoted cancer cell growth in both VCaP 
and LuCaP-147 cells (Extended Data Fig. 2c, d). The latter finding largely excludes that the over-expression 
system per se is the underlying cause of the synthetic sick relationship mentioned above. 
Next, we wondered if genetic or pharmacologic suppression of ERG signaling may revert the growth 
suppressing function of mutant SPOP in VCaP cells. Indeed, knockdown of ERG by short-hairpin RNA 




it promoted the growth of cells over-expressing SPOP-W131G (Extended Data Fig. 2e). In addition, low doses 
of the ETS inhibitor YK-4-279 promoted specifically the growth of VCaP cells over-expressing mutant SPOP 
(Fig. 1f). We noted a similar effect when VCaP cells were co-treated with a small molecule inhibitor of SPOP 
(Extended Data Fig. 2f)[225]. In aggregate, the data support an antagonistic relationship between oncogenic 
activation of ERG and a loss of SPOP function in prostate cancer cells.  
Mutant SPOP induced androgen receptor signaling antagonizes ERG activity 
In SPOP mutant prostate cancer, several dysregulated SPOP substrates (e.g. NCOA3, TRIM24, BET 
proteins) have been shown to boost the AR pathway [51, 127, 131, 139-141, 228, 254-256], leading ultimately 
to high levels of AR target genes and increased AR binding affinity in human tumor tissues (Extended Data 
Fig. 2g,h)[51, 257]. In contrast,  ERG-fused cancer cells express typically lower levels of AR target genes 
(Extended Data Fig. 2h)[51]. In line with this, the principle component analysis (PCA) of primary cancers also 
shows a marked difference in the transcriptional output of both tumor subtypes that remains detectable in 
advanced metastatic disease tissues and derived xenograft models (Extended Data Fig. 2i,j). 
We posited that differential levels of androgen receptor (AR) signaling in SPOP mutant versus ERG-fused 
cancers may be at the root of the incompatibility between these driver events. Thus, we analyzed the effect of 
mutant SPOP (SPOP-MTs; SPOP-Y87C, -F102C, -F133S) on AR- and ERG-related transcription in VCaP 
cells, and generated custom signatures using ChIP-seq data and matched RNA seq samples  (Supplementary 
Table 1)[258]. As expected, SPOP-MTs increased the transcription of genes bound by AR and induced by its 
ligand dihydrotestosterone (DHT), whereas genes bound by AR and repressed by DHT were further reduced 
(Fig. 2a, Extended Data Fig. 3a, b, and Supplementary Data Table 1). Remarkably, we observed the opposite 
effect on genes bound only by ERG. Mutant SPOP downregulated ERG-induced genes (e.g. MYC) and 
upregulated ERG-repressed genes, respectively (Fig. 1d). In line with these findings, we found the most 
striking transcriptional changes in co-bound genes linked to cellular differentiation and cell cycle arrest that 
are directly induced by DHT and repressed by ERG (e.g. HOXA genes, CDKN1A/p21, Fig. 1d, Fig. 2b, 
Extended Data Fig. 3b, c).  
The dramatic upregulation of this geneset was paralleled by a downregulation of cell cycle genes (e.g. E2F 




ERG targets, cell differentiation and the synthetic sick relationship of ERG and mutant SPOP (Fig. 1d, Fig. 
2c, Extended Data Fig. 3d-e).  
Conversely, we assessed the consequence of ERG over-expression in LNCaP cells under low DHT levels 
where mutant SPOP triggers AR signaling and tumor growth (Extended Data Fig. 3f,g)[140, 141]. Over-
expression of ΔERG in this setting robustly reverted the induction of signatures related to cell proliferation 
(e.g. E2F and MYC targets) and AR signaling. Taken together, the data implies a reciprocal incompatibility of 
mutant SPOP induced AR signaling and the function of the ERG oncogene.  
Next, we verified if corresponding transcriptional changes were found in clinical tissue samples. Indeed, 
ERG-regulated genes culled from VCaP cells were up-regulated in ERG-fused  and down-regulated in SPOP-
mutant primary tumors (Fig. 2d, Extended Data Fig. 4a)[51]. Importantly, the most striking changes between 
the two groups were found again in the AR/ERG co-bound gene set in primary prostate cancers (Extended 
Data Fig. 4b)[49, 51]. The results underscore both the relevance of our cell culture-based data and highlight 
the transcriptional differences among ERG- and SPOP-driven tumors.  
ZMYND11 is a SPOP substrate that induces AR and represses ERG transcription  
Using tandem mass tag (TMT)-based quantitative mass-spectrometry, we set out to search for SPOP 
substrates that may influence the activity of AR and ERG and thereby may cause to the synthetic sick 
relationship between mutant SPOP and ERG in VCaP cells overexpressing mutant SPOP (SPOP-MTs; SPOP-
Y87C, -F102C, -W131G, Extended Data Fig. 4c). Because recurrent loss-of-function SPOP mutants impair 
substrate ubiquitylation and proteasomal degradation, we searched for proteins which expression levels 
increase without concomitant increase in mRNA levels (Fig. 3a, Extended Data Fig. 4c, d). Overall, we noted 
a strong correlation of protein with mRNA expression changes with consistent changes of our AR and ERG 
custom signatures at the protein level (Fig. 3a., Extended Data Fig. 4e). In addition, we found a marked 
upregulation of the known SPOP substrate and AR activator TRIM24 at the protein level (Fig. 1c & 3a, 
Supplementary Table 2)[141, 255] and subsequently assessed if TRIM24 and more generally AR is implicated 
in the synthetic sick relationship between mutant SPOP and ERG. Indeed, knockdown of TRIM24 by two 
short hairpin RNAs partially reverted the growth inhibition mediated by mutant-SPOP in VCaP cells and 




cellular growth (Extended Data Fig. 4h, i).  
The most striking upregulation was noted for the bromodomain histone reader ZMYND11 (Fig. 3a, 
Extended Data Fig. 4d). In line with a SPOP substrate, wild type SPOP bound, ubiquitylated and decreased 
the expression of HA-ZYMND11 in a proteasome-dependent manner (Extended Data Fig. 5a, b). We found 
two degron sequences that were required for efficient SPOP-mediated ubiquitylation and protein degradation 
(Extended Data Fig. 5c-f). As expected, SPOP mutants failed to bind and adequately ubiquitylate HA-
ZMNYD11-WT (Extended Data Fig. 5g-i)[127, 131, 147, 228, 249, 254-256]. Finally, we confirmed that 
expression of mutant SPOP prolonged the half-life of endogenous ZMYND11 in VCaP cells and upregulated 
ZMYND11 expression in other prostate cancer cells (Extended Data Fig. 5j, k).  
Next, we assessed if ZMYND11 protein upregulation also contributed to the synthetic sick relationship. 
In support, forced expression of the degron-deficient variants of ZMYND11 (HA-ZMYND11-DMT1/DMT2) 
was sufficient to diminish the growth of VCaP cells (Fig. 3b, Extended Data Fig. 6a, b), while knockdown of 
ZMYND11 partially reverted the growth inhibition mediated by mutant SPOP (Fig. 3c).  
 We postulated that ZMYND11 up-regulation could contribute to the synthetic sick relationship by 
repressing the transcriptional activity of the ERG oncogene or enhancing AR signaling. To this end, expression 
changes induced by HA-ZMYND11-DMT2 largely overlapped with genes perturbed by mutant SPOP while 
the opposite was noted when ZMYND11 expression was reduced by RNA interference (Fig. 3c, d, Extended 
Data Fig. 6c). In comparison to mutant SPOP, AR and ERG target genes were similarly dysregulated by HA-
ZMYND11-DMT2 (Fig. 3e). Because the PWWP domain of ZMYND11 has been involved in the regulation 
of transcription through its ability to bind H3K36me3 histone marks [259], we tested the contribution of this 
domain to the overall transcriptional output. Indeed, the PCA of VCaP cells over-expressing either HA-
ZMYND11-DMT2 or a PWWP domain deficient mutant (W294A) revealed a major contribution of this 
domain to the ZMYND11 induced transcriptional changes (Extended Data Fig. 6d).  We subsequently mapped 
the genomic occupancy of ZMYND11 in VCaP cells expressing the SPOP-Y87C mutant by chromatin 
immunoprecipitation sequencing (ChIP-seq) and found an enrichment of ZMYND11 binding sites at promoter 
regions controlling ERG-induced genes (e.g. MYC,) and AR/ERG co-bound genes (e.g. p21/CDKN1A) (Fig. 




signaling and repressing ERG signaling downstream of mutant SPOP.    
Wild type SPOP is required for ERG oncogenic function 
We reasoned that ERG-driven tumors might require wild type SPOP to degrade ZMYND11 and thereby 
unlock the oncogenic function of ERG. In support, over-expression of wild type SPOP increased the 3D growth 
of mouse prostate epithelial organoids and VCaP cells only when ERG was over-expressed (Fig. 1b, Extended 
Data Fig. 2e, 7a, b). Remarkably, ERG-fused human tumor tissues displayed also the highest SPOP mRNAs 
levels (Fig. 4a). Thus, we wondered if ERG itself may directly upregulate SPOP transcription to support its 
own oncogenic activity. Indeed, mining ERG ChIP-seq data in VCaP cells revealed ERG bindings sites in the 
promoter region of SPOP (Extended Data Fig. 7c). Moreover, knockdown of ERG reduced SPOP protein 
levels in VCaP cells, while forced expression of a ERG led to the upregulation of SPOP mRNA and protein 
levels in PC3 cells (Fig. 4b, Extended Data Fig. 2e, 7d).  
We then asked if the elevated SPOP levels in the context of forced ΔERG expression have a functional 
impact on the oncogenic activity of ΔERG in the androgen-independent PC3 cells, in which ERG promotes 
tumor cell invasion [260]. Indeed, the reduction of SPOP levels by RNA interference reduced the ability of 
ΔERG to invade into matrigel (Fig. 4c). Similarly, knockdown of SPOP in VCaP cells reduced cell growth in 
3D cell culture and impaired ERG-mediated gene transcription (Extended Data Fig. 7e, f). In accordance with 
the ability of mutant SPOP to repress the function of endogenous wild type SPOP in a dominant-negative 
manner, the over-expression of mutant SPOP (SPOP-Y87C, -F102C, -W131G, -F133S) phenocopied the effect 
of SPOP knockdown on ERG-mediated invasion in PC3 cells (Extended Data Fig. 7g, h). In agreement with 
the established repressive function of ZMYND11 on ERG, we found that over-expression of HA-ZMNYD11-
DM2 was sufficient to repress ERG-induced invasion and established target genes in PC3 cells (Fig. 4d, e). 
Taken together, the data imply the existence of a positive feed-forward loop, in which ΔERG promotes the 
expression of SPOP to sustain its oncogenic activity.  
ERG and mutant SPOP trigger different responses to therapeutic interventions  
Based on the above-mentioned differences in tumorigenesis, we speculated that ERG or mutant SPOP 




type SPOP function, we hypothesized that ERG-fusion positive cells may be particularly sensitive to 
pharmacological inhibition of SPOP. We analyzed the response of the SPOP small molecule inhibitor 
compound 6b (SPOP-i) in ERG-fused, SPOP mutant and other prostate cancer cell lines and patient-derived 
xenograft models (PDX) [225]. The SPOP inhibitor increased the protein but not the mRNA levels of 
established SPOP substrates and ZMNYD11 while the related inactive analog compound 6c did not (Extended 
Data Fig. 8a-c). The latter did also not exert any activity in 3D culture models (Extended Data Fig. 8d). In 
agreement with our previous results, we found that ERG-fused cells (VCaP, LuCaP-23.1, -35) were more 
sensitive to SPOP-i than ERG-negative cells (22Rv1, LNCaP, PC3), while SPOP mutant cells (LuCaP-78, -
147) were particularly insensitive in 3D culture models and in xenograft tumor models in vivo (Fig. 5a and 
Extended Data Fig. 8e-j). Strikingly, the sensitivity to SPOP-i in vivo correlated well with ERG protein 
expression levels in the respective ERG-fusion positive cell line and PDX model (Fig. 5b). We further validated 
our results in the mouse prostate epithelial organoids and confirmed the increased sensitivity of ΔERG-
expressing cells to SPOP inhibition in this isogenic system (Fig. 5c).  
Given the notion that wild type SPOP dampens AR function in the context of ERG to sustain tumor growth, 
we asked if VCaP cells are particularly susceptible to increased DHT levels. Indeed, exposure to high-dose of 
testosterone in vivo or DHT in vitro induced similar molecular changes as for the over-expression of mutant 
SPOP and greatly suppressed the growth of ERG-fusion positive cells but not of SPOP mutant cells in vitro 
and in vivo (Fig. 1c, 5a, d and Extended Data Fig. 9a-i). In analogy to SPOP inhibition, the sensitivity to high 
testosterone in vivo correlated very well with ERG protein expression levels in the respective ERG-fusion 
positive cell line and PDX models (Fig. 5b). The data suggests a therapeutic opportunity for SPOP inhibition 
or high-dose androgen therapy in prostate cancers that express high levels of ERG.   
Conversely, and because SPOP mutant cancers are driven predominantly by androgen signaling and 
consequently display high-level activation of AR-related transcripts in human tumor tissues, we speculated 
that these tumors may be particular susceptible to androgen deprivation or anti-androgen therapies (ADT) 
(Extended Data Fig. 2h). Indeed, the prevalence of SPOP mutations in primary tumors -and tumors that had 
progressed after initial surgery or radiotherapy- is consistently higher as compared to tumors that had become 




9j). In line with the notion that this difference may be related to a better response of SPOP mutant tumors to 
ADT, SPOP mutant tumor display a trend towards better overall survival despite progressing faster after initial 
therapy (Extended Data Fig. 9k, l). To functionally analyze the response of androgen deprivation or the anti-
androgen enzalutamide, we chose to ectopically expressed different SPOP variants and ΔERG in the androgen-
dependent human LAPC4 prostate cancer cells that are wild-type for both driver genes. In accordance with the 
clinical observation, the presence of mutant SPOP (SPOP-Y87C, SPOP-W131G) rendered LAPC4 cells more 
susceptible to either ADT or enzalutamide in comparison to cells expressing control vector (Fig. 5e, Extended 
Data Fig. 9m). In contrast, ΔERG rendered the same cells more resistant to enzalutamide. In line with the 
previous findings in VCaP and LuCaP-147 cells, ΔERG expression rendered LAPC4 cells susceptible to high 
levels of DHT, while mutant SPOP had the opposite effect (Extended Data Fig. 9m). Taken together, the 
different responses to established and experimental therapeutic modalities observed between mutant SPOP and 
ERG add further credence to their divergent roles of the AR pathway related to tumorigenesis. 
DISCUSSION 
Although multiple studies over recent years have uncovered different genetically-defined subtypes of 
primary prostate cancer, their biological understanding and therapeutic implications remain largely unexplored 
territory. Here, we report two diametrically different paths toward tumorigenesis triggered by either highly 
recurrent missense mutation in SPOP or gene fusion involving the ERG oncogene. Importantly, wild type 
SPOP emerges as a critical component that enforces oncogenic ERG signaling in part through dampening AR 
activity, while mutant SPOP drives tumorigenesis through activation of AR signaling. In addition, we show 
that the bromodomain histone reader ZMYND11 is a SPOP substrate implicated downstream of SPOP in the 
opposing regulation of the ERG and AR pathway in the two tumor subtypes (Extended Data Fig. 10a). The 
AR and ERG pathways have been previously reported to have a partially antagonistic relationship [261, 262], 
further corroborating our findings.  
Because activation of the androgen receptor by androgens represents a key lineage specific oncogenic 
pathway in prostate cancer, androgen deprivation/antagonization therapies (ADT) remain the uniform 
treatment modality up to this very day. That said, the responses to ADT are highly variable and may last from 




mutations influence the treatment response. Most notably, SPOP mutations promote susceptibility to androgen 
deprivations therapies. In agreement with our findings, earlier reports have shown underrepresentation of 
SPOP mutant tumors in cohorts of castration-resistant disease and a more favorable response to the abiraterone 
and enzalutamide[102, 263].  
Conversely, we show that the presence of the ERG oncogene increases the susceptibility of tumor cells to 
high-dose androgen therapy, while cells expressing mutant SPOP remain largely unaffected. This is of clinical 
interest because testosterone treatment of patients with advanced castration-resistant disease has recently 
shown to trigger anti-tumor responses in around one third of the patients[264]. It is tempting to speculate that 
these insights may help to discern responders from non-responders.   
In addition, we provide evidence that the antagonistic relationship between mutant SPOP and ERG may 
be used towards the development of new therapeutic avenues.  More specifically, we show that ERG-driven 
cancer cells are particularly sensitive to the inhibition of wild-type SPOP using recently developed small 
molecule inhibitors[225]. Our preclinical data suggests that SPOP inhibition may be effective in clinical 
settings where ERG is robustly expressed (e.g. neo-adjuvant setting or early metastatic disease).  
More generally, our results identify another paradigm for antagonistic driver genes in prostate cancer that 
has recently emerged also for other cancer types [265-267]. In analogy to prostate cancer, truncal point 
mutations in DNMT3A and gene fusions in PML-RARA are mutually exclusive drivers in acute myeloid 
leukemia (AML). Similarly to SPOP, intact DNMT3A has been found to be critical for PML-RARA-driven 
leukemia (Extended Data Fig. 10b, c) [268, 269]. Importantly, we demonstrate here for prostate cancer that 
the concept of antagonistic driver genes can be exploited to identify therapeutic opportunities. 
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Methods 
Cell culture, Transfection and Infection 
VCaP, LNCaP, PC3, 22Rv1, HEK293 cells were purchased from ATCC. LAPC-4 were a gift from Prof. 
Helmut Klocker. VCaP and HEK293 were grown in DMEM with Glutamax (Gibco); LNCaP, PC3, 22Rv1, 




10% charcoal-stripped serum (CSS; One Shot Fetal Bovine Serum, Charcoal Strippped, Gibco) for androgen 
deprivation therapy response, and 1% Penicilin/Streptomycin. LuCaP-147 were grown in StemPro medium ( 
hESC SFM StemPro, Gibco) with regular supplements. All cells were incubated at 37°C and 5% CO2 and 
routinely tested for mycoplasma contamination. 
For stable knockdown experiments, cells were infected with pLKO-1 vectors (Sigma) and the following clones 
were used; SPOP: TRCN0000140431 (shSPOP_1) and TRCN000013911 (shSPOP_2); TRIM24: 
TRCN000021262 (shTRIM24_1) and TRCN0000195528 (shTRIM24_2); ERG: TRCN0000429354 
(shERG_1) and TRCN0000432394 (shERG_2); ZMYND11: TRCN0000275479 (shZMYND11_1) and 
TRCN0000275542 (shZMYND11_2). After infection, cells were selected in the presence of puromycin (2 
g/ml).  
For SPOP, ΔERG, HA-ZMYND11-WT, HA-ZMYND11-DMT1, HA-ZMYND11-DMT2, MYC and AR 
over-expression a derivate of the pLX304 vector was used throughout in which the CMV promoter has been 
exchanged to a PGK promoter and the blasticidin cassette left unchanged (ΔERG constructs) or exchanged by 
a puromycin resistance cassette (SPOP constructs) (pLX_TRC_307, available at Addgene as Plasmid 41392, 
pCW107). All ORFs were cloned into pLX_TRC_307 using Nhe1 and Mlu1. Tumors from PDX LuCaP-78, -
147, -35,-23.1 were collected,  dissociated and cultured as previosly described[270]. 
Chemicals 
MG-132 (M7449) and Cycloheximide (CHX, C4859) were purchased from Sigma and used at 20 M and 100 
g/ml in all experiments, respectively. SPOP inhibitor (SPOP-i, compound 6b) and its inactive analog 
(compound 6c), were provided by the laboratory of C. Yang (State Key Laboratory of Drug Research, Shanghai 
Institute of Materia Medica). DHT (5α-Dihydrotestosterone) was purchased from Sigma (D-073), MDV3100 
(Enzalutamide) was purchased from APExBIO (A3003). YK-4-279 (ETS inhibitor) was purchased from 
Selleckchem. All chemicals were used at the indicated concentration. 
Dose-response curves and cell-growth assays 
Cells were seeded (between 1x103 and 1x104 per well) in a 96-well plate. Cells were subsequently treated with 




dose-response curves or were left untreated for cell-growth assays. Proliferation at corresponding time points 
was assessed by MTT (Methylthiazolyldiphenyl-tetrazolium bromide) assay according to the manufacturer’s 
recommendations (Sigma). For each time point, absorbance (OD, 590 nm) was measured in a microplate 
reader.  
Matrigel Invasion assay 
Invasion assay was performed as previously described[271]. Briefly, equal number of PC3 cells were seeded 
into 10cm dishes and starved with a medium without fetal bovine serum for 24 hr.; subsequently 1x105 cells 
were resuspended in 100 µl of starved medium and seeded onto the basement of a Boyden chamber (CLS3422; 
Sigma) coated with Matrigel. RPMI with 10% fetal bovine serum was added to the lower chamber. After 48hr, 
invaded cells were fixed with 10% of formalin and stained with crystal violet. Absorbance was measured at 
560 nm. 
Clonogenic assay in methylcellulose 
Cells were seeded (between 5x103 and 1x104) in methylcellulose (Methocult H4100, StemCell Technologies) 
in triplicate. Cells were left untreated for cell-growth assay. For SPOP inhibitor assay, cells were treated with 
vehicle (0.1% DMSO) or drug (SPOP-i) at corresponding concentration. For androgen therapy, cells were 
treated with vehicle (0.01% Methanol) or DHT at corresponding concentration. Cells were incubated at 37°C 
and 5% CO2 for 7-28 days and colonies were stained with MTT solution at 37°C overnight and absorbance 
(OD, 590 nm) was measured in a microplate reader.  
Mouse Prostate Organoid Generation and Experiments 
Prostate tissue was extracted from euthanized mice, digested and seeded in Matrigel as previously 
described[272]. To overexpress SPOP species and ΔERG genes, mouse prostate cells were virally infected by 
spinoculation for 1hr at 600g at 32 °C and selected with puromycin. For the ‘‘organoid formation assay’’ 
1.5x104 single cells were plated per well onto 40µl of Matrigel on day 1 and  organoids were grown in Revised 
human prostate organoids medium as previously described[270]. The number of formed organoids that reached 
100 μM of diameter was counted on days 14 post plating with cellSens software (Olympus). For the Dose-




(0.1% DMSO) or drug (SPOP-i) at indicated concentration for 7 days. Live/dead staining was purchased from 
Promega (G9711) and performed according to the manufacturer’s protocol. The genetically engineered Mouse 
Prostate Organoids, derived from PbCre;R26F133V , were generated as previosly described[139] 
Immunohistochemistry 
Cytoblocks were prepared from the pellets of organoids by adding plasma and thrombin in order to obtain a 
solid matrix. Once solidified, the organoids were fixed in 10% formalin (Thermo Scientific, 5701) and 
embedded in paraffin as a normal tissue. Sections of 4 μm were used for IHC analyses and hematoxylin and 
eosin (H&E) staining (Diapath, C0303) and (Diapath, C0363) respectively. Once dried the sections were 
treated with OTTIX plus solution (Diapath, X0076) and OTTIX shaper solution (Diapath, X0096) to dewax 
and rehydrate the sections. Antigen retrieval was performed using pH 6 solutions at 98°C for 20 min. 
Successively the endogenous peroxidases and non-specific binding sites were blocked using 3% H2O2 (VWR 
chemicals, 23615.248) and Protein-Block solution (DAKO Agilent technologies, X0909) respectively, for 10 
min. Sections were then stained for anti-p16 (ab211542, Abcam, 1:1200), anti-Ki67 (Clone SP6; Lab Vision 
Corporation #RT-9106-R7, RTU). IHC analyses were performed using Imagescope software. 
In vivo experiments 
All animal experiments were carried out in male athymic nude mice (Balb/c nu/nu, 6-8 weeks old), NSG 
mice (NOD Scid Gamma, 6-8 weeks old), and NRG (NOD Rag gamma, 6-8 weeks old) accordingly to protocol 
approved by the Swiss Veterinary Authority (No. TI-14-2014, TI-38-2018, TI-39-2018 and TI-42-2018). 
Patient-derived xenografts (PDX) LuCaP-147, -78, -35, -23 were  provided by Eva Corey (University of 
Washington) and maintained as previously described[273]. 2x106 VCaP cells, 5x106 LuCaP-147, LuCaP-23.1, 
LuCaP-35 and LuCaP-78 were resuspended in 100 l of PBS and Matrigel 1/1 and subcutaneously injected 
into both of the dorsal flanks of the mice. Tumor growth was recorded using digital caliper and tumor volumes 
were calculated using the formula (L x W 2) /2, where L=length and W=width of tumor. For the testosterone 
propionate (25mg/kg) and SPOP inhibitor (SPOP-i, 50mg/kg) treatment, the mice were grouped randomly and 
the treatment started when the mean tumor volume reached 100m3. Tumor volume and weight were measured 
2 times per week. Testosterone propionate was resuspended first in ethanol (150mg/kg) and then in Corn oil 




buffered saline (PBS) at a final concentration of 50 mg/kg. At the end of the experiment, mice were euthanized, 
tumors extracted and weighted. Testosterone level was measured using the Human Testosterone ELISA Kit 
from Abcam (ab174569). In order to recapitulate the levels of supraphysiological testosterone administrated 
in clinical trials[264], mice reaching at least 3 times the testosterone levels measured before the treatment 
initiated were included in the depicted data. 
Antibodies, Immunoblotting, and Immunoprecipiation 
Antibodies used in immunoblotting and immunoprecipitation assays were: anti-SPOP (ab81163, Abcam), 
anti-TRIM24 (Sc-271266, Santa Cruz), anti-ß-ACTIN (4967, Cell Signaling), anti-AR (Sc-7305, Santa Cruz), 
anti-GADPH (Sc-47724, Santa Cruz), anti-ERG (Sc-271048, Santa Cruz), anti-VCL (SAB1404522, Sigma), 
anti-ZMYND11 (NBP2-20960, Novus Biologicals), anti-HA (H3663, Sigma), anti-BRD2 (A302-583A, 
Bethyl Labs), anti-NCOA3 (2126, Cell Signaling), anti-DEK (610948, BDBioscience), anti-p21 (2947S, Cell 
Signaling) , anti-c-MYC (5605S, Cell Signaling), anti-HOXB13 (Sc-28333, Santa Cruz), anti-PTEN (9559, 
cell signaling), anti-p21 (ab188224, Abcam), anti-HOXB13 (NBP2-43655, Novus biologicals). All antibodies 
were employed at dilutions suggested by the manufacturers.  
For immunoblotting, cells were washed with PBS and subsequently lysed in RIPA buffer (Sigma) and 
sonicated. Protein concentration was determined using the BCA reagent (ThermoFisher), same amounts of 
protein were separated by SDS-PAGE (Biorad) and transferred onto PVDF membrane (ThermoScientific). 
The membrane was incubated for one hour in 5% nonfat dry milk/TBS-T blocking buffer followed by 
incubation with the primary antibody overnight at 4°C. The membrane was washed with TBS-T followed by 
incubation with horseradish peroxidase-conjugated secondary antibody (Promega).  
To detect interactions of SPOP and ZMYND11, cells were lysed in 1 % NP40 buffer (50mM Tris-HCl pH 
7.4, 150 mM NaCl, 1 % NP40) with 2x protease inhibitor cocktail (Complete, Roche), sonicated, and 3 mg of 
lysate were incubated overnight with 2 μg of anti-HA-tag or control mouse IgG antibody (sc-2025, Santa Cruz 
Biotechnology) at 4 °C. Subsequently, antibodies were collected by 25 μl protein A/G magnetic beads (88803, 
Fisher Scientific) for 2h, followed by 2 washing steps with 1 % NP40 buffer. Proteins were eluted by addition 
of 1x SDS-sample buffer under reducing conditions at 95 °C for 5 min. 




293T cells were transiently transfected with indicated plasmids: pCW107-HA-ZMYND11-WT or HA-
ZYMND11-DMT1/DMT2 (2 g), pCW107-SPOP-WT or SPOP-MT (2 g), CMV-8x Ubi-His (2 g). 42 
hours later, cells were treated with MG-132 (20μM) or DMSO for additional 7 hours. Cells were then washed 
with PBS and collected by centrifugation. Small amount of cells was lysed in RIPA buffer and the rest in 
Buffer C (6M guanidine –HCL, 0.1 M Na2HPO4/NaH2PO4, 10mM Imidazole, pH=8). The whole cells extract 
was sonicated and incubated with 60 l of Ni-NTA agarose (Sigma) overnight at 4°C. Next, Ni-NTA beads 
were washed once with Buffer C, twice with Buffer D (1 volume of Buffer C: 3 volumes of Buffer E) and once 
with Buffer E (25 mMTris-HCL, 20 mM Imidazole, pH=6.8). Elution of bound proteins was processed by 
boiling in 1x SDS loading buffer containing 300 mM Imidazole. Samples were loaded, separated by SDS-
PAGE, and detected by immunoblotting. 
 
Gene Expression Studies 
RNA was extracted using the RNeasy kit (Qiagen) and processed by Kapa SybrFAST one-Step qRT-PCR 
kit according to manufacturer`s instructions. qRT-PCR was undertaken on an Applied Biosystems 
StepOnePlus System. The target mRNA expression was quantified using ∆∆Ct method and normalized to 
Actin expression. The following primers were used: SPOP, forward 5’- 
GAAATGGTGTTTGCGAGTAAACC-3’, reverse 5`-TACCTACGCTTCCAGTCTCTG-3’; ERG, forward 
5’-TGTATGCCAGCATTTGTTTCTT-3’, reverse 5’- TTGCTGGTCTTGCCATTCCT-3’;  β-ACTIN, 
forward 5’-AAGGAGCCCCACGAAAAAT-3’, reverse 5’-ACCGAACTTGCATTGATTCCAG-3’; PLAU, 
forward 5’- TACGGCTCTGAAGTCACCACCAAAAT-3’, reverse 5’-
CCCCAGCTCACAATTCCAGTCAA-3’; PLAT, forward 5’-CACTGGGCCTGGGCAAACATA-3’, reverse 
5’-CACGTCAGCCTGCGGTTCTTC-3’; TMPRSS2, forward 5’-CAGGAGTGTACGGGAATGTGATGGT-
3’, reverse 5’-GATTAGCCGTCTGCCCTCATTTGT-3’; KLK2, forward 5’- CTGCCCATTGCCTAA 
AGAAG-3’, reverse 5’- GTAGAGCGGGTGTGGGAAG-3’; PSA forward 5’- 
GAGCACCCCTATCAACCCCCTATT -3’ , reverse 5’- AGCAACCCTGGACCTCACACCTAA-3’; 
ZMYND11, forward 5’-ATGGCACGTTTAACAAAAAGACG-3’, reverse 5’-
CGGTCAATGTTGGCAATCTGC-3’; BRD2, forward 5’-CTACGTAAGAAACCCCGGAAG-3’, reverse 5’-




5’-GTGTTGGGAACTTGGATAACTGG-3; NCOA3, forward 5’-AGACGGGAGCAGGAAAGTAAA-3’,  
reverse 5’-GTAAAAGCGGTCCTAAGGAGTC-3’; DEK, forward 5’-AACTGCTTTACAACAGGCCAG-3’  
, reverse 5’-ATGGTTTGCCAGAAGGCTTTG-3’. 
RNA-Seq of VCaP, LNCaP and LuCaP cells  
RNA sequencing for all experiments involving LuCaP xenografts, VCaP and LNCaP cells was performed 
at the Institute of Oncology Research using Next Ultra II Directional RNA Library Prep Kit for Illumina and 
sequenced on the Illumina NextSeq500 with single-end, 75 base pair long reads. The overall quality of 
sequencing reads was evaluated using a variety of tools, namely FastQC (Andrews S., 2010), RSeQC[274], 
AfterQC[275] and Qualimap[276]. Sequence alignments to the reference human genome (GRCh38) was 
performed using STAR [277] (v.2.5.2a). Gene-expression was quantified at gene level by using the 
comprehensive annotations made available by Gencode[278]. Specifically, we used v27 release of the Gene 
Transfer File (GTF). Raw-counts were further processed in the R Statistical environment and downstream 
differential expression analysis was performed using the DESeq2[279] pipeline.   
Genes being expressed at very low levels were automatically filtered out through the Independent 
Filtering feature embedded in DESeq2 (alpha = 0.05). Differential-expression results were ranked according 
to the computed Wald-statistics values. Subsequently, gene-set enrichment testing was performed using 
Camera[280] pre-ranked (inter-gene correlation equal to 0.1, parametric test procedure). Statistical 
enrichments were assessed for gene-sets belonging to the Hallmark collection, which is curated by the 
Molecular Signature DataBase[281, 282] (MSigDB), and for custom ERG and DHT-specific gene-signatures. 
All enrichments were corrected for multiple testing using Benjamini and Hochberg FDR adjusted p-value.  
Identification of ERG and AR related gene signatures 
We retrieved RNA-seq data from GEO Dataset GSE83652[252] to identify transcriptional perturbations 
in VCaP cells following treatment with DHT or following silencing of ERG. To this purpose we completely 
reprocessed samples SRR3713255-57, SRR3713267-72 using STAR and DESeq2 as previously described for 
VCaP cells. In addition, to identify direct targets, we integrated information relative to AR and ERG chromatin 




reduce false negatives, we merged results of experiments performed at different time points, namely 2h and 
18h after DHT exposure. De-multiplexed reads were aligned to hg38 release of the human reference genome 
using bwa-mem[283] (0.7.15). MACS[284] (v.2.1.0) was used to perform peak calling procedure using a cutoff 
FDR q-value of 0.01 and a mappable genome size optimized for hg38 equal to 2.9 gigabases. Downstream 
analysis was performed in R statistical environment. We identified binding sites overlapping promoters by 
using bedtools[285].  
Promoters were defined as DNA regions ranging from 1500 bp upstream to 500 bp downstream of 
Transcription Start Sites (TSSs).  
To discriminate between ERG- and AR- specific transcriptional responses we stratified genes into three main 
classes: genes whose promoter regions are bound by AR but not by ERG, genes whose promoters are bound 
by ERG but not by AR, and finally, genes whose promoters are co-bound by both AR and ERG. AR bound 
only genes were further subdivided into two sets, those being significantly (FDR<0.05) induced following 
DHT treatment and those being significantly repressed. A similar approach was applied to ERG bound only 
genes, where genes were subdivided into ERG-induced and ERG-repressed gene-sets, if they were respectively 
down or up-regulated following ERG silencing. To be more stringent in the definition of AR-specific and 
ERG-specific signatures, we excluded genes from the ERG-induced set that were also significantly up-
regulated following DHT treatment, vice-versa we excluded ERG-repressed genes that were significantly 
down-regulated following DHT-treatment. The same criteria were applied for DHT-specific gene-sets. Finally, 
defined an additional gene-set (DHT-induced/ERG-repressed) consisting of genes being co-bound by AR and 
ERG in their promoter region, which were significantly up-regulated following DHT treatment but also 
significantly upregulated following ERG-silencing. All gene-sets are detailed in Supplementary Table 1. 
Overlap between custom derived gene-signatures and the most represented Hallmark’s gene-sets was assessed 
using GeneOverlap R package (Shen L, Sinai M, 2013). Two-dimensional network visualization was generated 
with Cytoscape. [286] 
Gene-set testing and RNA-Seq data processing of clinical samples 
Publicly available RNA-Seq data for primary prostate cancer were obtained from The Caner Genome 




counts, using TCGAbiolinks package[287]. We selected individuals characterized by either SPOP or ERG 
fusion, and a third group defined as “others”, which includes all remaining samples, excluding those patients 
exhibiting any other ETS-rearrangement. Differential expression and gene-set enrichment between samples 
harboring ERG fusions and SPOP-mutations were performed using DESeq2 and Camera (pre-ranked) as 
previously described for prostate cancer cells. Single-sample gene-set enrichment analysis (GSVA[288] 
package) was applied to measure, for each individual patient, the overall activity of the custom gene-sets that 
were previously generated in VCaP cells. Following differential expression analysis between ERG-rearranged 
and SPOP mutant primary tumors, we defined two gene-sets consisting of SPOP-upregulated (n = 443, log2FC 
>1, FDR<0.05) and ERG-upregulated (n = 359, log2FC >1, FDR<0.05) genes.  
PolyA+ RNASeq data for metastatic prostate cancer were obtained from SU2C cohort[56]. Normalized 
RPKM values, retrieved through cBioportal, were log transformed and patient’s categorization 
(SPOP/ERG/OTHER) was performed in the same manner as for primary tumors. To evaluate whether 
transcriptional differences occurring between ERG-rearranged and SPOP-mutant individuals were also 
conserved in CRPC setting, we quantified the above mentioned SPOP-upregulated/ERG-upregulated 
signatures in the SU2C 2019 cohort, using single-sample gene-set enrichment analysis. The obtained ssGSEA 
scores were scaled in a range between -1 and 1 (SPOP-Upregulated) and between 1 and -1 (ERG-upregulated, 
inverted). Subsequently we averaged these rescaled values in order to obtain an aggregate score.  
Circular representation of interactions between gene-sets 
Chord diagrams were generated using circlize[289] package in R statistical environment.  
Strings, whose thickness is proportional to the number of shared elements, represent common genes between 
sets. 
ZMYND11 ChIP-seq in VCaP cells  
ChIP-seq using anti-ZMYND11 antibody (NBP2-20960, Novus Biologicals) was performed in VCaP 
cells, overexpressing either wild-type SPOP or mutant SPOP harboring Y87C point mutation. Briefly, to 
isolate chromatin, cells (120.000.000 per IP) were cross-linked using 1% Formaldehyde cross-link protein-




room temperature followed by cell lysis and sonication, resulting in an average chromatin fragment size of 
200 bp. Samples lysis was performed as previously described using MNase enzyme 1000 gel units=1 uL[290]. 
After adding the MNase sonication buffer, the samples were sonicated for 30 cycles, 30 sec ON and 30 sec 
OFF at high voltage. ChIP and input DNA (50 ng) were used for indexed library preparation using NEBNext 
Ultra II DNA Library Prep kit and subjected to 75 bp single-end sequencing on the Illumina NextSeq500. All 
procedures were performed at the Institute of Oncology Research.  De-multiplexed reads were aligned to hg38 
release of the human reference genome using bwa-mem[283] (0.7.15). MACS[284] (v.2.1.0) was used to 
perform peak calling procedure using a cutoff FDR q-value of 0.01 and a mappable genome size optimized for 
hg38 equal to 2.9 gigabases.  Downstream analysis was performed in R statistical environment.  
ChIPseeker[291] was used to annotate peaks and to represent the distribution of ZMYND11 binding sites 
relative to Transcription Start Sites (TSSs). The R package chipenrich[292] was subsequently used to 
determine enrichment or depletion of ZMYND11 peaks in regions surrounding TSSs of genes that are included 
in Hallmarks or custom gene-set collections. Surrounding regions were defined as ranging from 5kb upstream 
to 5kb downstream of their TSSs (locusdef = 5kb), which is in line with the overall behavior of ZMYND11 
binding sites around TSSs (Extended Data Fig. 6f-g).  
Identification of AR-binding sites in primary prostate cancer specimen  
Publicly available ChIP-Seq data were retrieved from GSE1207383. ChIP-seq data were reprocessed as 
described for ZMYND11 samples. Differential binding affinity of AR between ERG-rearranged and SPOP-
mutant tumors was performed using DiffBind (Stark R and Brown G, 2011).  
Frequency of SPOP mutations across patients’ cohorts 
We defined the percentage of SPOP-mutant and TMPRSS2-ERG positive tumors across different 
patients’ cohorts originating from multiple sources. Patients with primary/loco-regional prostate tumors were 
derived from TCGA and MSK-IMPACT Clinical Sequencing cohorts[102]. Patients with tumor-progression 
(non-castrate) were derived from MSK-IMPACT and TCGA cohorts, by including from the latter only 
individuals that showed tumor-progression based on survival information. Castration resistant prostate cancer 
patients were retrieved from MSK-IMPACT, Beltran et. al[58] and from the SU2C[56] .datasets. 




neuroendocrine features) and from Beltran et al[58].  Total number of SPOP-mutant and TMPRSS2-ERG 
tumors were determined based on the clinical annotations of the individual studies and integrated with fusion 
information from TCGA Fusion Gene Database (www.tumorfusions.org). Survival analysis was performed in 
R statistical environment using the TCGA and MSK-IMPACT clinical sequencing cohort.  
Quantitative liquid-chromatography-mass spectrometry (LC-MS/MS) 
In solution digestion VCaP cell pellets were lysed at 4 ºC in 8 M urea, 50 mM Tris-HCl pH  8.0, 150 mM 
NaCl, 1 mM EDTA, 2 µg/µl aprotinin (Sigma-Aldrich), 10 µg/µl leupeptin (Roche), and 1 mM 
phenylmethylsulfonyl fluoride (PMSF) (Sigma). Protein concentration was determined using a bicinchoninic 
acid (BCA) protein assay (Pierce). Proteins were reduced with 5 mM (DTT) for 45 min at room temperature 
(RT), followed by alkylation with 10 mM iodoacetamide for 30 min at room temperature in the dark. The urea 
concentration was reduced to 2 M using 50 mM Tris-HCl, pH 8. Samples were digested for 2 h at 25 ºC with 
endoproteinase Lys-C (Wako Laboratories) at an enzyme-to-substrate ratio of 1:50. Samples were 
subsequently digested overnight at 25 ºC with sequencing grade trypsin (Promega) at an enzyme-to-substrate 
ratio of 1:50. Following overnight digestion, samples were acidified to a final concentration of 1% formic acid.  
Peptide samples were desalted on a 100 mg tC18 Sep-Pak SPE cartridge (Waters). Cartridges were 
conditioned with 1 mL of 100% MeCN, 1 mL of 50% MeCN/0.1% FA, and 4x with 1 mL of 0.1% TFA. The 
sample was loaded, and washed 3x with 1 mL of 0.1% TFA, 1x with 1 mL of 1% FA, and eluted 2x with 600 
µl of 50% MeCN/0.1% FA.  
TMT labeling of peptides 
Peptides were labeled with TMT 10-plex isobaric mass tagging reagents (Thermo Fisher Scientific). Each 
TMT reagent was resuspended in 41 µL of MeCN. Peptides were resuspended in 100 µL of 50 mM HEPES 
and combined with TMT reagent. Samples were incubated at RT for 1 h while shaking. The TMT reaction was 
quenched with 8 µL of 5% hydroxylamine at RT for 15 min with shaking. TMT labeled samples were 
combined, dried to completion, reconstituted in 100 µL of 0.1% FA, and desalted on StageTips or 100 mg 
SepPak columns as described above. 




The TMT labeled samples were fractionated using offline high pH reversed-phase 
chromatography (bRP) as previously described [Mertins et al Nat Prot]. Samples were fractionated using 
Zorbax 300 Extend C18 column (4.6 × 250 mm, 300 Å, 5 μm, Agilent) on an Agilent 1100 series high-pressure 
liquid chromatography (HPLC) system. Samples were reconstituted in 900 µL of 4.5 mM ammonium formate 
(pH 10) in 2% (vol/vol) acetonitrile (MeCN) (bRP solvent A). Samples were injected with Solvent A at a flow 
rate of 1 mL/min and separated using a 96 min gradient. The gradient consisted of an initial increase to 16% 
solvent B (90% MeCN, 5 mM ammonium formate, pH 10), followed by 60 min linear gradient from 16% 
solvent B to 40% B and successive ramps to 44% and 60% at a flow rate of 1 mL/min. Fractions were collected 
in a 96-deep well plate (GE Healthcare) and pooled in a non-contiguous manner into final 24 proteome 
fractions. Pooled fractions were dried to completeness using a SpeedVac concentrator. 
Liquid chromatography and mass spectrometry 
Desalted peptides were resuspended in 3% MeCN/0.1% FA and analyzed by online nanoflow liquid 
chromatography tandem mass spectrometry (LC-MS/MS) using Q-Exactive plus mass spectrometer (Thermo 
Fisher Scientific) coupled on-line to a Proxeon Easy-nLC 1200 as previously described [Mertins et al Nature 
Protocols]. Briefly, 1 ug of each sample was loaded onto a microcapillary column (360 μm outer diameter × 
75 μm inner diameter) containing an integrated electrospray emitter tip (10 μm), packed to approximately 22 
cm with ReproSil-Pur C18-AQ 1.9 μm beads (Dr. Maisch GmbH) and heated to 50 ºC. Samples were analyzed 
with 110 min LC-MS method. The 110 min method contained a mobile phase with a flow rate of 200 nL/min, 
comprised of 3% acetonitrile/0.1% formic acid (Solvent A) and 90% acetonitrile/0.1% formic acid (Solvent 
B), with the following gradient profile: (min:%B) 0:2; 1:6; 85:30; 94:60; 95:90; 100:90; 101:50; 110:50 (the 
last two steps at 500 nL/min flow rate). The Q-Exactive plus MS was operated in the data-dependent mode 
acquiring HCD MS/MS scans (r =35,000) after each MS1 scan (r = 70,000) on the 12 most abundant precursor 
ions using an MS1 target of 3 × 10^6  and an MS2 target of 5 × 10^4 . The maximum ion time utilized for 
MS/MS scans was 120 ms; the HCD-normalized collision energy was set to 30; the dynamic exclusion time 
was set to 20 s, isotope exclusion function was enabled, and peptide match function was set to preferred. 
Charge exclusion was enabled for charge states that were unassigned, 1 and >6. 




All data were analyzed using Spectrum Mill software package v 6.1 pre-release (Agilent Technologies). 
Similar MS/MS spectra acquired on the same precursor m/z within +/- 60 s were merged. MS/MS spectra were 
excluded from searching if they were not within the precursor MH+ range of 750-4000 Da or if they failed the 
quality filter by not having a sequence tag length >0. MS/MS spectra were searched against UniProt human 
database. All spectra were allowed +/- 20 ppm mass tolerance for precursor and product ions, 30% minimum 
matched peak intensity, and “trypsin allow P” enzyme specificity with up to 4 missed cleavages. The fixed 
modifications were carbamidomethylation at cysteine, and TMT at N-termini and internal lysine residues. 
Variable modifications included oxidized methionine and N-terminal protein acetylation. Individual spectra 
were automatically designated as confidently assigned using the Spectrum Mill autovalidation module. 
Specifically, a target-decoy based false-discovery rate (FDR) scoring threshold criteria via a two-step auto 
threshold strategy at the spectral and protein levels was used. First, peptide mode was set to allow automatic 
variable range precursor mass filtering with score thresholds optimized to yield a spectral level FDR of 1 %. 
A protein polishing autovalidation was applied to further filter the peptide spectrum matches using a target 
protein-level FDR threshold of 0. Following autovalidation, a protein-protein comparison table was generated, 
which contained experimental ratios. For all experiments, non-human contaminants and reversed hits were 
removed. Furthermore, data were filtered to only consider proteins with 2 or more unique peptides and was 
median normalized.  
Statistical analysis 
GraphPad Prism version 8.3 (GraphPad Software) was used for statistical analysis. Data are depicted as 
mean + s.e.m. unless otherwise specified. The number of independent experiments or mice used is indicated 
in each figure legends. Unpaired Student’s t-test was used for comparisons between two groups, one-way 
analysis of variance (ANOVA) with multiple comparisons for two groups or more, and two-way ANOVA with 
multiple comparisons for repeated measurements. Multiple comparisons tests were corrected by controlling 
the False Discovery Rate (FDR) using Benjamini and Hochberg’s method. . Correlation analyses were 





The original mass spectra have been deposited in the public proteomics repository MassIVE and are 
accessible at ftp://MSV000082915@massive.ucsd.edu when providing the dataset password: prostate. If 
requested, also provide the username: MSV000082915. This data will be made public upon acceptance of the 
manuscript. 
RNA-Seq data generated have been deposited in the ArrayExpress database at EMBL-EBI and were 
assigned the accessions E-MTAB-7165, E-MTAB-7170, E-MTAB-7173. These data are accessible when 
providing the datasets username and password as follow:   
Username: Reviewer_E-MTAB-7165 Password: 4sJqpicv  
Username: Reviewer_E-MTAB-7170 Password: AAA65MMy 
Username: Reviewer_E-MTAB-7173 Password: sIpcob0o.  
CHiP-Seq data generated have been deposited in the ArrayExpress database at EMBL-EBI and were 
assigned the accessions E-MTAB-7174. These data are accessible when providing the dataset username and 
password as follow:  
Username: Reviewer_E-MTAB-7174 Password: onwwwwni 







Figure 1. Genetic alterations in SPOP and ERG are synthetic sick. a, Distribution of genetic alterations in 
SPOP and ERG across 333 primary prostate cancers in TCGA database[51]. b, 3D growth of mouse prostate 
epithelial organoids derived from C57BL/6  mice over-expressing the indicated SPOP and ERG species (bar 




sections are shown. c, In  vivo  growth of VCaP  xenografts over‐expressing  the  indicated  SPOP  species  in 
immune‐compromised mice (each group, n=10). d, Immunoblot of VCaP cells over-expressing the indicated 
SPOP species and corresponding quantification of the indicated protein levels depicted as heatmap. Protein 
expression changes were normalized to β-ACTIN and Control cell line. e, Tumor growth kinetics of xenografts 
established from LuCaP-147 PDX (SPOP-Y83C) stably overexpressing ΔERG or Control vector (each group, 
n=10). Corresponding immunoblot and quantification depicted as heatmap. Protein expression changes were 
normalized to Vinculin (VCL) and Control cell line. f, Dose-response curve of VCaP cells overexpressing the 
indicated SPOP species and treated with the ETS-inhibitor YK-4-279. All error bars, mean + s.e.m. P values 
were determined by one-way ANOVA (b) or two-way ANOVA (c,e,f) with multiple comparisons and adjusted 






Figure 2. Mutant SPOP-induced androgen receptor signaling antagonizes ERG activity. a, Gene-set 
enrichment analysis of VCaP cells overexpressing SPOP mutant (SPOP-MTs; SPOP-Y87C, -F102C, -W131G) 




for each condition. Enrichments are determined on custom gene-sets of direct androgen receptor (AR) and 
ERG target genes (Supplemental Table 1). Enrichments and FDR-adjusted p-values are computed with 
Camera (pre-ranked) b, Venn Diagram and heatmap depicting the expression of genes included in the custom 
gene‐set  of  AR/ERG  co‐bound  genes  that  are  repressed  by  ERG  and  induced  by  DHT  in  VCaP  cells 
overexpressing  SPOP‐MTs  (SPOP‐Y87C,  F102C, W131G),  SPOP‐WT  and  vector Control. Genes  (rows)  and 
samples  (columns)  were  clustered  using  Euclidean  distance.  Gene  expression  values,  normalized  using 
variance  stabilizing  transformation  (vst) were  scaled  and  centered  by  row  prior  of  clustering.  Columns 














Figure 3. ZMYND11 is a SPOP substrate and influences AR- and ERG-dependent gene transcription. 
a, Scatter plot of SPOP-MTs (average across SPOP-Y87C, -F102C, -W131G) versus SPOP-WT transcriptome 
(n=3, biological replicates) and proteome expression changes in VCaP cells (n=2, biological replicates). Genes 
from custom signature DHT-Induced/ERG-Repressed genes (AR+ERG co-bound) are highlighted in red. 
TRIM24 and ZMYND11 are the most upregulated proteins without changes at mRNA levels and are 
highlighted in green. CDKN1A (p21) upregulated at both mRNA and protein levels, and MYC downregulated 
at both mRNA and protein levels, are highlighted in black. b, 2D proliferation assay of VCaP cancer cells 
overexpressing HA‐ZMNYD11‐WT  and  derived  degron‐deficient mutants  (DMT1/2)  (n=3). Corresponding 
immunoblot of indicated proteins. Correlation between cell viability and  ZMYND11 protein expression 
changes (Prot. Exp. Changes), as quantified by immunoblot in the same cell lines. P values were calculated 




indicated SPOP species with and without ZMYND11 knockdown using two different short hairpin RNAs, at 
day 16 (n=3). Protein expression of the indicated proteins was analyzed by immunoblotting. d, Chord-diagram 
of transcriptionally regulated genes by either SPOP-MTs or HA-ZMYND11-DMT2 in VCaP cells 
(FDR<0.05). Strings, whose thickness is proportional to the number of shared elements, represent common 
genes between sets. e,  Gene‐set  enrichment  analysis  of  VCaP  cell  overexpressing  HA‐ZMYND11‐DMT2 
compared to Control, based on RNA‐seq data. Enrichments are performed on custom gene‐sets of direct 
androgen  receptor  (AR)  and  ERG  target  genes.  FDR‐adjusted  p‐values  are  computed with  Camera  (pre‐
ranked). f, Heatmap of ChIP-seq signals around TSS regions (+/- 4kb) at which ZMYND11 bindings were 
identified by peak calling procedure (Macs2). g, IGV-derived screenshots representing loglikelihood ratio of 
ZMYND11 bindings in mutant SPOP (SPOP-Y87C) vs wild-type SPOP over-expressing VCaP cells. Reported 










Figure 4. SPOP-WT is an ERG target gene and required for ERG-mediated cell invasion. a, SPOP 
mRNA expression levels in 333 primary prostate cancer tissues stratified according to the indicated driver 
mutations[51]. Error bars, mean ± s.d. b, SPOP mRNA and protein levels in response to forced expression of 
ΔERG in PC3 prostate cancer cells by qPCR and immunoblotting, respectively. Error bars, mean + s.e.m. 
(n=3). P values were determined by unpaired, two‐tailed Student’s t‐test. #P < 0.05; Control versus ΔERG for 
SPOP expression levels. ***P < 0.001; Control versus ΔERG for ERG expression levels. c, Transwell Matrigel 
invasion assay of PC3 cells with forced expression of ΔERG and knockdown of SPOP using two different 
short hairpin RNAs. Protein expression of the indicated proteins was assessed in parallel by immunoblotting. 
Error bars, mean ± s.e.m. (n=3). d, Transwell Matrigel invasion assay of PC3 cells with forced expression of 
ΔERG and HA-ZMYND11-DMT2 and corresponding immunoblot analysis. Error bars, mean ± s.e.m. (n=3). 
e, Analysis of the ΔERG- and HA-ZMYND11-DMT2-induced transcriptional changes in the ERG target genes 












Fig. 8f‐j and 9e‐i. b, Correlation of sensitivity to SPOP-i or testosterone treatment shown in Extended Data 




















Extended Data Figure 1. Genetic alterations in SPOP and ERG are mutually exclusive across metastatic 
prostate cancers and synthetic sick. a, Distribution of genetic alterations in SPOP and ERG transcription 
factor across 150 and 61 metastatic prostate cancer, respectively[49, 50]. b,c,  Immunoblot expression analysis 
of indicated proteins in mouse prostate organoids over expressing indicated SPOP mutants (MTs) and ΔERG 
and corresponding live and dead staining (bar 20 µm).  Ki67 and p16 immunohistochemistry and 
corresponding quantification. d, 3D colony formation assay in methylcellulose of LAPC4 human prostate 
cancer cells over-expressing the indicated SPOP MTs and corresponding immunoblot (n=3). e, Immunoblot 
of indicated proteins in Wild-type, SPOP-F133V-CRE negative and SPOP  F133V-CRE positive organoids 
line derived from SPOP F133V transgenic mouse model. f,g, 3D growth in methylcellulose (n=5) and 2D 
proliferation assay of TMPRSS2-ERG positive VCaP human prostate cancer cells over-expressing the indicated 
SPOP MTs. h, Corresponding mitotic count by DAPI (bar represents 100 µm). All error bars, mean + s.e.m. P 
values were determined by one-way ANOVA (d,f,h) or two-way ANOVA  (g) with multiple comparisons and 










Extended Data Figure 2. Antagonistic relationship between oncogenic activation of ERG and loss of 
SPOP function in prostate cancer cells. a,b, 2D (a) and 3D (b) proliferation assay of LuCAP-147 ( SPOP-
Y83C) PDX cells overexpressing ΔERG and corresponding immunoblot (n=3). c, 3D proliferation assay of 
VCaP cells overexpressing MYC (n=2). d, 2D proliferation assay of LuCaP-147 overexpressing MYC (n=3) 
and corresponding immunoblot. e, 3D proliferation assay of VCaP cells overexpressing SPOP-WT and SPOP-
131G , with or without  knockdown of ERG with a short hairpin RNA ( shERG_1) and corresponding 
quantification and immunoblot ( n=3). f, 2D proliferation assay of VCaP cells treated with SPOP-i (compound 
6b) and  ETS inhibitor (compound YK-4-279). Cell viability was assessed 4 days after treatment. Pictures are 
representative and have been taken after incubation with MTT reagent (bar 200 µm). g, The Box plots show 
distribution of normalized reads in binding sites over all the identified differentially bound (DB) regions (FDR 
= 0.0)5 in ERG-fused (violet) vs SPOP-mutant (green) samples. P-values were determined using Wilcoxon-
test.  h, AR score of primary prostate tumors ERG or SPOP mutant’s positive (TCGA)[51, 293]. i, PCA-
analysis based on RNA-Seq derived mRNA expression levels (TCGA cohort). ERG-fused (violet) and SPOP-
mutant (green). Individuals were annotated into subtypes as described in Material and Methods.  j, The 
boxplots represent transcriptional activity of SPOP integrated-signature (see Materials and Methods) in CRPC 
samples (SU2C-2019 cohort, left) and PDX-models. Scores are determined using integrated signatures derived 
from primary prostate tumors (TCGA-cohort). ERG-fused samples are depicted in violet, SPOP-mutants 
samples are depicted in green. Samples not harboring SPOP mutations or ERG rearrangements are represented 
in grey. P values were determined using Wilcoxon-test, and adjusted for multiple comparisons (FDR).  All 
error bars, mean + s.e.m. P values were determined by an unpaired, two-tailed Student’s t-test (b,c) or two-
way ANOVA  (a, c, d, e, f) with multiple comparisons and adjusted using Benjamini-Hochberg post-test. *P 









Extended Data Figure 3. Gene expression and pathway analysis related to the synthetic sick relationship 
between mutant SPOP and ERG in VCaP cells. a, Gene-set enrichment analysis of SPOP mutants (-MTs) 
overexpressing VCaP cells compared to control, based on RNASeq data. Enrichments are performed on 
custom gene-sets of direct androgen receptor (AR) and ERG target genes. FDR-adjusted p-values are computed 
with Camera (pre-ranked) b, Left: Exemplified tracks of genes bound by AR (green) and/or ERG (violet) 
derived from custom ERG and AR signatures determined in VCaP cells (see Materials and Methods). Right: 
Heatmap showing mRNA expression of MYC, CDKN1A, CORO1B and PGC in control, wild-type and SPOP-
mutant VCaP cells. Columns represent average expression across replicates.  c, Enrichment analysis of gene 
ontology (GO) biological processes in the AR/ERG co-bound gene set, induced or repressed by ERG. d, Gene-
set enrichment analysis of SPOP-mutants (-MTs) compared to SPOP-wild type (-WT) overexpressing VCaP 
cells, based on RNASeq data. Enrichments are performed on Hallmark gene-sets and FDR-adjusted p-values 
are determined with Camera (pre-ranked). e, Gene-set enrichment analysis of SPOP-mutants (-MTs) compared 
to Control VCaP cells, based on RNASeq data. Enrichments are performed on Hallmark gene-sets and FDR-
adjusted p-values are determined with Camera (pre-ranked). f, Gene set enrichment analysis of LNCaP cells 
overexpressing either mutant (SPOP-MTs, SPOP-Y87C, or wild-type SPOP, in presence or absence of 
concomitant ΔERG expression. FDR-adjusted p-values were computed with Camera (pre-ranked). g, 
Corresponding relative mRNA expression level of SPOP and ERG measured by qPCR (f). Cells were 









Extended Data Figure 4. Direct AR and ERG target gene expression changes in human tumor tissues. 
a, Heatmap of individual tumors based on single sample GSEA scores as shown in Fig. 2d. Values were scaled 
and centered by row. Association of individuals to subtypes was performed as described in Materials and 
Methods. b, Enrichment analysis of direct AR and ERG target genes in primary prostate cancers[49]. FDR-
adjusted p-values are determined with Camera (pre-ranked). Association of individuals to subtypes was 
performed as described in Materials and Methods.  c, Schematic illustration showing the design of the 
proteomics experiments. Tandem Mass Tag (TMT)-based quantitative mass-spectrometry (n=2, biological 
replicates) was used in VCaP cells overexpressing Control vector (Control), SPOP-WT, or three different 
SPOP mutants (SPOP-Y87C, SPOP-F102C and SPOP-W131G). d, Protein expression changes in VCaP cells 
over-expressing SPOP-WT compared to SPOP mutants (average of SPOP-Y87C, -F102C, W-131G). Top 
proteins being upregulated are highlighted in red (GDF15, TMPRSS2, ZMYND11, TRIM24). e, Scatter plot 
of SPOP-MTs (average across SPOP-Y87C, -F102C, -W131G) versus SPOP-WT transcriptome and proteome 
expression changes in VCaP cells (n=2 biological replicates). Custom gene signatures changes are highlighted. 
AR bound only genes being DHT induced (red) or DHT repressed (blue) in left panel; ERG bound only genes 
being ERG induced ( red), or ERG repressed (blue) in right panel f,, 2D proliferation assay of VCaP cancer 
cells over-expressing the indicated SPOP mutants with and without TRIM24 knockdown using two different 
short hairpin RNAs. Expression of the indicated proteins was analyzed by immunoblotting (n=3). g, AR target 
genes expression changes in VCaP cells overexpressing SPOP-Y87C with and without TRIM24 knockdown 
using two different short hairpin RNAs. h,i , 2D (f) and 3D (g) proliferation assay of VCaP cancer cells over-
expressing AR (n=3). All error bars, mean + s.e.m. P values were determined by unpaired, two-tailed Student’s 
t-test (i) or two-way ANOVA  (f,h) with multiple comparisons and adjusted using Benjamini-Hochberg post-









Extended Data Figure 5. ZMYND11 is a SPOP substrate. a, Over-expression of HA-ZMYND11 and 
SPOP-WT in 293T cells and subsequent expression analysis of the indicated proteins by immunoblotting. b, 
Whole cell extracts (WCE) of 293T cells over-expressing HA-ZMYND11-WT and different SPOP species 
and corresponding anti-HA-immunoprecipitation (HA-IP). Expression of the indicated proteins was analyzed 
by immunoblotting. c, Domain structure of ZMYND11 with indicated SPOP-degron and ubiquitin sites. d, 
Schematic illustration of the SPOP degron sequences on ZMYND11. The degron-deficient mutants (DMT) 
were generated by two serine-to-alanine substitutions. e, Forced expression of SPOP-WT together with HA-
ZMYND11-WT or two degron deficient mutants (DMT1 & DMT2) in 293T cells. f, In vivo ubiquitylation 
assay of HA-ZMYND11 in 293T cells. Cell were transiently transfected with the indicated constructs and 
histidine-tagged (his-tag), ubiquitylated proteins were pulled down using nickel beads. Ubiquitylated HA-
tagged ZMYND11 was detected by immunoblotting. g, Over-expression of HA-ZMYND11 and SPOP-Y87C 
in 293T cells and subsequent expression analysis of the indicated proteins by immunoblotting after 
proteasomal inhibition with MG132. h, Whole cell extracts (WCE) and corresponding anti-HA-
immunoprecipitation (HA-IP) of 293T cells over-expressing HA-ZMYND11-WT and different SPOP-MTs 
species as indicated. Expression of the indicated proteins was analyzed by immunoblotting. i, In vivo 
ubiquitylation assay of HA-ZMYND11 in 293T cells. Cell were transiently transfected with the indicated 
constructs and histidine-tagged (his-tag), ubiquitylated proteins were pulled down using nickel beads. 
Ubiquitylated HA-tagged ZMYND11 was detected by immunoblotting.   j, Immunoblots and quantification of 
indicated protein expression changes after treatment with cycloheximide (CHX, 100 µg/mL) in VCaP cells 
overexpressing the indicated SPOP species (n=2).  All error bars, mean + s.e.m . Time is indicated in hours 
(h). k, Immunoblots of indicated proteins in VCaP, LNCaP and LAPC4 human prostate cancer cells 









Extended Data Figure 6. ZMYND11 influences ERG target genes transcription. a, mRNA expression 
levels of VCaP cancer cells over-expressing HA-ZMNYD11-WT and derived degron-deficient mutants 
(DMT1/2) measured by qPCR. b, Corresponding 3D colony formation assay in methylcellulose (n=3). Error 
bars, mean ± s.e.m P values were determined by one-way ANOVA with multiple comparisons and adjusted 
using Benjamini-Hochberg post-test . ***P < 0.001. c, Chord diagram of genes transcriptionally regulated by 
either mutant SPOP (SPOP-MTs, SPOP-Y87C, -F102C, -W131G) or knockdown of ZMYND11 by two 
different short hairpin RNAs (shZMYND11 sh1/sh2 ; shZMYND11_1 and shZMYND11_2) in VCaP cells 
(FDR<0.05). Strings, whose thickness is proportional to the number of shared elements, represent common 
genes between sets. d, PCA-analysis based on RNA-Seq derived mRNA expression levels of the differentially 
expressed genes identified from the comparison between SPOP-mutant and SPOP-wild type overexpressing 
VCaP cells (FDR<0.05). Samples from the same experiment are shown: Controls (grey), HA-ZMYND11-
DMT2 (red) HA-ZMYND11-DMT2-W294A (blue). Right: corresponding immunoblot. Molecular weights 
are indicated in kilodaltons (kDa). e, Number of genomic ZMYND11 peaks measured by ChIP sequencing in 
VCaP cells overexpressing SPOP-mutant (SPOP-Y87C), SPOP-wild type (-WT) and control vector (Control). 
f, Density plots representing ZMYND11 read count frequency respective to TSSs (+/- 5kb) as determined from 
ChIP-Sequencing experiments. Top: Control VCaP cells; Center: VCaP cells overexpressing SPOP-WT;  
Bottom: VCaP cells overexpressing Y87C SPOP mutation. g, Localization of ZMYND11 binding sites, 
stratified according to genomic regions.  h, Enrichment analysis, performed using chipenrich[292], of genes 
identified by ChIP-Seq to contain ZMYND11 peaks (within 5 kb flanking each of their TSSs), performed on 
AR- and ERG-derived gene sets in VCaP cells overexpressing SPOP-Y87C. i, IGV-derived screenshots 
representing chromatin binding sites of ZMYND11 on MYC (UP) and CDKN1A (bottom) as determined from 
ChIP-Seq experiments in VCaP cells overexpressing either wildtype (light pink) or mutant-SPOP (Y87C, dark 





Extended Data Figure 7 
 
Extended Data Figure 7. SPOP is transcriptionally up-regulated by ERG and wild type SPOP is 
required for ERG-mediated oncogenic phenotypes. a,b, mRNA expression  of VCaP cancer cells over-
expressing SPOP-WT in the context of ERG knockdown with one short hairpin RNA (a) and corresponding 
3D proliferation assay in response to DHT treatment (b). Cells were plated in medium supplemented with 10% 
charcoal-stripped serum (CSS medium). c, IGV screenshot of the SPOP promoter showing ERG binding sites 




immunoblot expression analysis of the indicated proteins. e, Knockdown of SPOP with two different short 
hairpin RNAs in VCaP cells followed by immunoblot expression analysis of the indicated proteins and 
corresponding 3D growth in methylcellulose. f, Gene-set enrichment analysis of SPOP knockdown compared 
to shControl VCaP cells, based on RNA-Seq data. Enrichments are performed on custom gene-sets of direct 
androgen receptor (AR) and ERG target genes. FDR-adjusted p-values are computed with Camera (pre-
ranked). g, Transwell invasion assay of PC3 cells over-expressing ΔERG and indicated SPOP mutants. 
Corresponding protein expression changes assessed by immunoblotting (n=3). h, Corresponding mRNA 
analysis of the ERG target genes PLAU and PLAT measured by qPCR. All error bars, mean + s.e.m. P values 
were determined by unpaired, two-tailed Student’s t-test (b) , one-way ANOVA (e, g) or two-way ANOVA  
(h) with multiple comparisons and adjusted using Benjamini-Hochberg post-test. NS, not significant. *P < 
0.05, **P < 0.01, ***P < 0.001; PLAT expression levels in Control versus each cell line ., #P < 0.05, ##P < 








Extended Data Figure 8. ERG-positive tumor cells are particularly sensitive to SPOP inhibition. a, 
Immunoblot expression analysis of indicated SPOP substrates upon treatment with SPOP inhibitor (SPOP-i, 
compound 6b ) in VCaP cells. b, Corresponding mRNA expression analysis of SPOP substrates by qPCR. c, 
Immunoblot expression analysis of indicated SPOP substrates upon treatment with SPOP-6c (inactive analog 
of compound 6b) in VCaP cells. d, 3D colony formation assay in methylcellulose of VCaP and LuCaP-147 
cells upon SPOP-6c treatment. e, SPOP-i-mediated 3D growth inhibition in methylcellulose in the indicated 
prostate cancer cell lines. Error bars, mean ± s.e.m. f, Tumor growth kinetics with (n =10) or without (vehicle; 
n = 10) SPOP-i treatment in xenografts established from LuCaP-147 (SPOP-Y83C) PDX cells and 
corresponding immunoblot. g, Tumor growth kinetics with (n = 4) or without (vehicle; n = 4) SPOP-i treatment 
in xenografts established from LuCaP-78 ( SPOP-W131G) PDX cells and corresponding immunoblot. h, 
Tumor growth kinetics with (n = 11) or without (vehicle; n = 11) SPOP-i treatment in xenografts established 
from VCaP cells and corresponding immunoblot. i, Tumor growth kinetics with (n = 8) or without (vehicle; n 
= 10) SPOP-i treatment in LuCaP-35  ( ERG-positive) PDX and corresponding Immunoblot. j, Tumor growth 
kinetics with (n = 6) or without (vehicle; n = 8) SPOP-i treatment in LuCaP-23.1 (ERG-positive) PDX and 
corresponding immunoblot. All SPOP-i treatment initiated when tumors reached an average of 100mm3.  All 
error bars, mean + s.e.m. P values were determined by two-way ANOVA (f, g, h, i, j,) with multiple 









Extended Data Figure 9. ERG and mutant SPOP trigger opposite responses to High-Dose Androgen 
Therapy. a, Immunoblot expression analysis of VCaP cell line treated for 7 days with DMSO or DHT 
(100nM). Cells were cultured in normal growth culture medium (DMEM Glutamax + 10% FBS). b, Gene-set 
enrichment analysis of DHT-treated (100 nM) VCaP cells compared to control (DMSO), based on RNASeq 
data. Enrichments are performed on custom gene-sets of direct androgen receptor (AR) and ERG target genes. 
FDR-adjusted p-values are computed with Camera (pre-ranked). c, 3D proliferation assay of VCaP (ERG 
positive) and LuCaP-147 (SPOP-Y83C) PDX cells in response to high doses of dihydrostestosterone (DHT). 
Cells were seeded in normal medium (DMEM Glutamax + 10% FBS and StemPro respectively) and treated 
once with corresponding DHT concentration. Error bars, mean ± s.e.m.  d, Testosterone levels measured in 
mice before and after 7 days of daily treatment. Error bars, mean ± s.e.m. e, Tumor growth kinetics with (n = 
6) or without (vehicle; n = 6) testosterone treatment in xenografts established from VCaP (ERG positive) cells 
and corresponding immunoblot. Treatment initiated when tumors reached 100mm3. f, Tumor growth kinetics 
with (n = 10) or without (vehicle; n = 10) testosterone treatment in xenografts established from LuCaP-147 
(SPOP-Y83C) cells and corresponding immunoblot. Treatment initiated when tumors reached 100mm3. g, 
Tumor growth kinetics with (n = 4) or without (vehicle; n = 4) testosterone treatment in xenografts established 
from LuCaP-78 (SPOP-W131G) cells and corresponding immunoblot. Treatment initiated when tumors 
reached 100mm3. h, Tumor growth kinetics with (n = 10) or without (vehicle; n = 10) testosterone treatment 
in xenografts established from LuCaP-35 cells and corresponding immunoblot. Treatment initiated when 
tumors reached 100mm3. i, Tumor growth kinetics with (n =12) or without (vehicle; n = 12) testosterone 
treatment in xenografts established from LuCaP-23.1 cells and corresponding immunoblot. j, Bar plots indicate 
the relative frequency of SPOP-mutant and TMPRSS2-ERG positive tumors across composite primary, 
progressed, castration-resistant and neuroendocrine patients’ cohorts (PRIM = primary; PROG = progressed; 
CRPC = castration resistant; NEPC = neuroendocrine)[56, 58, 102]. Statistical significance between the 
expected frequencies observed within primary tumors and those observed in castration resistant prostate cancer 
was determined by chi-squared k, Progression-free survival of prostate cancer patients derived from the 
TCGA-cohort. Curves representing TMPRSS2-ERG rearranged and SPOP-mutant patients are indicated in 
violet and green, respectively. The area around the curves represents 80% confidence interval. The bar plot in 
the lower left corner indicates the percentage of SPOP-mutant tumors within all patients who were diagnosed 
with prostate cancer (DIAG) and within the individuals who developed a progression of the disease (PROG). 
l. Overall survival of prostate cancer patients derived from the MSK-IMPACT cohort. Curves representing 
TMPRSS2-ERG rearranged and SPOP-mutant patients are indicated in violet and green, respectively. The area 
around the curves represents 80% confidence interval. The bar plot in the lower left corner indicates the 
percentage of SPOP-mutant tumors within all patients who were diagnosed with prostate cancer (DIAG), 
within individuals who developed a metastatic progression of the disease (PROG), and within individuals who 
developed castration-resistant prostate cancer (CRPC). m, Response to androgen deprivation or high androgen 
treatment (100nm DHT) of LAPC4 cells overexpressing ΔERG or indicated SPOP mutants species (Y87C, 
W131G) in 2D cell culture and corresponding immunoblot. Cells were cultured in CSS (charcoal-stripped 
serum) medium and DHT was added at the corresponding concentration. Viability was assessed after 7 days. 
***P < 0.001.; Control versus each cell line under androgen stimulation. ###P < 0.001; Control versus each cell 
line under androgen deprivation. All error bars, mean + s.e.m unless otherwise specified. P values were 
determined by two-way ANOVA (c, e, f, g, h, i, m) with multiple comparisons and adjusted using Benjamini-





Extended Data Figure 10 
 
Extended Data Figure 10.  SPOP and ERG are part of a distinct class of antagonistic driver genes. a, 
Schematic representation of the proposed model for the aversive relationship between mutant SPOP and ERG 
in prostate cancer. b, Distribution of genetic alterations in RARA and DNMT3 across 151 acute myeloid 
leukemia patients in TCGA database[269]. c, Boxplots showing RNA-Seq based mRNA expression levels of 
DNMT3A among acute myeloid leukemia patients, stratified according to presence/absence of PML-RARA 
fusion and DNMT3A mutation status. d, PCA-analysis based on RNA-Seq derived mRNA expression levels 
of the top 1000 most variable genes of the TCGA-AML cohort. RARA-fused (violet) and DNMT3A-mutant 
(green).  
 
